CA2298651A1 - 1-¬4-(substituted alkoxy)benzyl|naphthalene compounds having estrogen inhibitory activity - Google Patents
1-¬4-(substituted alkoxy)benzyl|naphthalene compounds having estrogen inhibitory activity Download PDFInfo
- Publication number
- CA2298651A1 CA2298651A1 CA002298651A CA2298651A CA2298651A1 CA 2298651 A1 CA2298651 A1 CA 2298651A1 CA 002298651 A CA002298651 A CA 002298651A CA 2298651 A CA2298651 A CA 2298651A CA 2298651 A1 CA2298651 A1 CA 2298651A1
- Authority
- CA
- Canada
- Prior art keywords
- hydroxyphenyl
- hydroxy
- naphthalene
- naphth
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940011871 estrogen Drugs 0.000 title description 28
- 239000000262 estrogen Substances 0.000 title description 28
- 230000002401 inhibitory effect Effects 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 82
- -1 1azepinyl Chemical group 0.000 claims abstract description 52
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 39
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 21
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims abstract description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 11
- 125000002252 acyl group Chemical group 0.000 claims abstract description 7
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 5
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims abstract description 5
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 4
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims abstract description 4
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract description 3
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims abstract description 3
- 125000001475 halogen functional group Chemical group 0.000 claims abstract 2
- 238000011321 prophylaxis Methods 0.000 claims abstract 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 76
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 49
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 42
- 125000004344 phenylpropyl group Chemical group 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
- KXECNBBTPNGMQB-UHFFFAOYSA-N 1-(4-chlorophenyl)-1-ethyl-3-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]urea Chemical compound C=1C=C(Cl)C=CC=1N(CC)C(=O)NCC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 KXECNBBTPNGMQB-UHFFFAOYSA-N 0.000 claims description 2
- VLZJAQBHXPQQEL-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-1-methylurea Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)NCC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 VLZJAQBHXPQQEL-UHFFFAOYSA-N 0.000 claims description 2
- OXUQHEMOZJKNIA-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]urea Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1CNC(=O)NC1=CC=C(Cl)C=C1 OXUQHEMOZJKNIA-UHFFFAOYSA-N 0.000 claims description 2
- GXMWCOJSCNNEBU-UHFFFAOYSA-N 1-[2-[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenoxy]ethyl]pyrrolidin-2-one Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCN1C(=O)CCC1 GXMWCOJSCNNEBU-UHFFFAOYSA-N 0.000 claims description 2
- ZILXERXGWWQAQO-UHFFFAOYSA-N 1-[4-[4-[3-[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenoxy]propyl]piperazin-1-yl]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1N1CCN(CCCOC=2C=CC(CC=3C4=CC=C(O)C=C4C=CC=3C=3C=CC(O)=CC=3)=CC=2)CC1 ZILXERXGWWQAQO-UHFFFAOYSA-N 0.000 claims description 2
- PWPMZKJQLQWKML-UHFFFAOYSA-N 1-[4-[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenoxy]butyl]pyrrolidin-2-one Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCN1C(=O)CCC1 PWPMZKJQLQWKML-UHFFFAOYSA-N 0.000 claims description 2
- TVHHMXLQPXZOCM-UHFFFAOYSA-N 1-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-1-methyl-3-(4-methylphenyl)urea Chemical compound C=1C=C(C)C=CC=1NC(=O)N(C)CC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 TVHHMXLQPXZOCM-UHFFFAOYSA-N 0.000 claims description 2
- BESRIIPAXQETRC-UHFFFAOYSA-N 1-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-1-methyl-3-phenylurea Chemical compound C=1C=CC=CC=1NC(=O)N(C)CC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 BESRIIPAXQETRC-UHFFFAOYSA-N 0.000 claims description 2
- MXDGJHDODNCYAE-UHFFFAOYSA-N 1-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-3-(4-hydroxyphenyl)-1-methylurea Chemical compound C=1C=C(O)C=CC=1NC(=O)N(C)CC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 MXDGJHDODNCYAE-UHFFFAOYSA-N 0.000 claims description 2
- QBYRZVPIWOXKPI-UHFFFAOYSA-N 1-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-3-(4-hydroxyphenyl)urea Chemical compound C1=CC(O)=CC=C1NC(=O)NCC(C=C1)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 QBYRZVPIWOXKPI-UHFFFAOYSA-N 0.000 claims description 2
- ILJCOOPYEYNISQ-UHFFFAOYSA-N 1-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-3-(4-methoxyphenyl)urea Chemical compound C1=CC(OC)=CC=C1NC(=O)NCC(C=C1)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 ILJCOOPYEYNISQ-UHFFFAOYSA-N 0.000 claims description 2
- LAMKPPRBOZUZNK-UHFFFAOYSA-N 1-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-3-(4-methylphenyl)urea Chemical compound C1=CC(C)=CC=C1NC(=O)NCC(C=C1)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 LAMKPPRBOZUZNK-UHFFFAOYSA-N 0.000 claims description 2
- REFMCLAHWBBEAE-UHFFFAOYSA-N 1-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-3-phenylurea Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1CNC(=O)NC1=CC=CC=C1 REFMCLAHWBBEAE-UHFFFAOYSA-N 0.000 claims description 2
- JXOXKMIFCIUCQN-UHFFFAOYSA-N 1-ethyl-1-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-3-(4-methylphenyl)urea Chemical compound C=1C=C(C)C=CC=1NC(=O)N(CC)CC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 JXOXKMIFCIUCQN-UHFFFAOYSA-N 0.000 claims description 2
- RNPPDBQZPMOGPW-UHFFFAOYSA-N 1-ethyl-3-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-1-(4-hydroxyphenyl)urea Chemical compound C=1C=C(O)C=CC=1N(CC)C(=O)NCC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 RNPPDBQZPMOGPW-UHFFFAOYSA-N 0.000 claims description 2
- CZWICFNOOAVUMH-UHFFFAOYSA-N 1-ethyl-3-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-1-(4-methylphenyl)urea Chemical compound C=1C=C(C)C=CC=1N(CC)C(=O)NCC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 CZWICFNOOAVUMH-UHFFFAOYSA-N 0.000 claims description 2
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 2
- QVBWNXGJTZAGPY-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-1-methylurea Chemical compound C=1C=C(Cl)C=CC=1NC(=O)N(C)CC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 QVBWNXGJTZAGPY-UHFFFAOYSA-N 0.000 claims description 2
- VAJRNQJMGKGBBS-UHFFFAOYSA-N 3-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-1-(4-hydroxyphenyl)-1-methylurea Chemical compound C=1C=C(O)C=CC=1N(C)C(=O)NCC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 VAJRNQJMGKGBBS-UHFFFAOYSA-N 0.000 claims description 2
- TTXULDDDPBAMPT-UHFFFAOYSA-N 3-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-1-(4-methoxyphenyl)-1-methylurea Chemical compound C1=CC(OC)=CC=C1N(C)C(=O)NCC(C=C1)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 TTXULDDDPBAMPT-UHFFFAOYSA-N 0.000 claims description 2
- GUACZUDEEJSRMC-UHFFFAOYSA-N 3-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-1-methyl-1-(4-methylphenyl)urea Chemical compound C=1C=C(C)C=CC=1N(C)C(=O)NCC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 GUACZUDEEJSRMC-UHFFFAOYSA-N 0.000 claims description 2
- BHNAJPMLCLBSLE-UHFFFAOYSA-N 3-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-1-methyl-1-phenylurea Chemical compound C=1C=CC=CC=1N(C)C(=O)NCC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 BHNAJPMLCLBSLE-UHFFFAOYSA-N 0.000 claims description 2
- YVVRZPOCLSVFTF-UHFFFAOYSA-N 5-[[4-(dimethylamino)phenyl]-methoxymethyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C=1C=C(O)C=CC=1C=1C=CC2=CC(O)=CC=C2C=1C(OC)C1=CC=C(N(C)C)C=C1 YVVRZPOCLSVFTF-UHFFFAOYSA-N 0.000 claims description 2
- IMJMNYIBNSVZLQ-UHFFFAOYSA-N 5-[[4-[2-(1h-azepin-2-yl)ethoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCC1=CC=CC=CN1 IMJMNYIBNSVZLQ-UHFFFAOYSA-N 0.000 claims description 2
- IDVQQLGXPWHRDF-UHFFFAOYSA-N 5-[[4-[2-(2,6-dimethylmorpholin-4-yl)ethoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1C(C)OC(C)CN1CCOC(C=C1)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 IDVQQLGXPWHRDF-UHFFFAOYSA-N 0.000 claims description 2
- HKHJWCXMXPVPDF-UHFFFAOYSA-N 5-[[4-[3-(1h-azepin-3-yl)propoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCC1=CNC=CC=C1 HKHJWCXMXPVPDF-UHFFFAOYSA-N 0.000 claims description 2
- ULOYQBHDTJLIOE-UHFFFAOYSA-N 5-[[4-[3-(2,6-dimethylmorpholin-4-yl)propoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1C(C)OC(C)CN1CCCOC(C=C1)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 ULOYQBHDTJLIOE-UHFFFAOYSA-N 0.000 claims description 2
- PVGYKCJGMWQCDS-UHFFFAOYSA-N 5-[[4-[3-(butylamino)propoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(OCCCNCCCC)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 PVGYKCJGMWQCDS-UHFFFAOYSA-N 0.000 claims description 2
- SMDRFXRSLRRBHG-UHFFFAOYSA-N 5-[[4-[3-(dibutylamino)propoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 SMDRFXRSLRRBHG-UHFFFAOYSA-N 0.000 claims description 2
- GKVFCMXIRLKFCT-UHFFFAOYSA-N 5-[[4-[3-[4-(4-chlorophenyl)piperazin-1-yl]propoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCN1CCN(C=2C=CC(Cl)=CC=2)CC1 GKVFCMXIRLKFCT-UHFFFAOYSA-N 0.000 claims description 2
- AJLQPJYQMFQOFL-UHFFFAOYSA-N 5-[[4-[3-[di(propan-2-yl)amino]propoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(OCCCN(C(C)C)C(C)C)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 AJLQPJYQMFQOFL-UHFFFAOYSA-N 0.000 claims description 2
- BWXLNWUIDRSFKW-UHFFFAOYSA-N 5-[[4-[4-(1h-azepin-2-yl)butoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCC1=CC=CC=CN1 BWXLNWUIDRSFKW-UHFFFAOYSA-N 0.000 claims description 2
- ZDHFLHDLNVWUNE-UHFFFAOYSA-N 5-[[4-[4-(1h-azepin-3-yl)butoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCC1=CNC=CC=C1 ZDHFLHDLNVWUNE-UHFFFAOYSA-N 0.000 claims description 2
- HQXXJHNSKIPYLE-UHFFFAOYSA-N 5-[[4-[4-(1h-azepin-4-yl)butoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCC1=CC=CNC=C1 HQXXJHNSKIPYLE-UHFFFAOYSA-N 0.000 claims description 2
- PZFOCFKTCSSZHC-UHFFFAOYSA-N 5-[[4-[4-(3-azaspiro[5.5]undecan-3-yl)butoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCN1CCC2(CCCCC2)CC1 PZFOCFKTCSSZHC-UHFFFAOYSA-N 0.000 claims description 2
- XBBGDEIGQOZMHA-UHFFFAOYSA-N 5-[[4-[6-(ethylamino)hexoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(OCCCCCCNCC)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 XBBGDEIGQOZMHA-UHFFFAOYSA-N 0.000 claims description 2
- MLYVVPDEOHXXAB-UHFFFAOYSA-N 5-[[4-[6-[di(propan-2-yl)amino]hexoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(OCCCCCCN(C(C)C)C(C)C)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 MLYVVPDEOHXXAB-UHFFFAOYSA-N 0.000 claims description 2
- YTTTVQKTOVYHEX-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(2-piperidin-2-ylethoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCC1NCCCC1 YTTTVQKTOVYHEX-UHFFFAOYSA-N 0.000 claims description 2
- YJIJXZGSABGTOJ-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(2-piperidin-4-ylethoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCC1CCNCC1 YJIJXZGSABGTOJ-UHFFFAOYSA-N 0.000 claims description 2
- HPBIZQWYIGBOIA-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(2-pyrrolidin-2-ylethoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCC1NCCC1 HPBIZQWYIGBOIA-UHFFFAOYSA-N 0.000 claims description 2
- LQPXZSLGQOOMQO-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(2-pyrrolidin-3-ylethoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCC1CNCC1 LQPXZSLGQOOMQO-UHFFFAOYSA-N 0.000 claims description 2
- KTPRJNYLISFYAZ-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(3-piperidin-2-ylpropoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCC1NCCCC1 KTPRJNYLISFYAZ-UHFFFAOYSA-N 0.000 claims description 2
- JPEHOTBDPLCRGW-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(3-piperidin-3-ylpropoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCC1CNCCC1 JPEHOTBDPLCRGW-UHFFFAOYSA-N 0.000 claims description 2
- WTBHFUIVOIGMKG-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(3-piperidin-4-ylpropoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCC1CCNCC1 WTBHFUIVOIGMKG-UHFFFAOYSA-N 0.000 claims description 2
- XSMIYYTYAXHAAY-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(3-pyrrolidin-3-ylpropoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCC1CNCC1 XSMIYYTYAXHAAY-UHFFFAOYSA-N 0.000 claims description 2
- HLGMPZWPOMLWJU-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(4-piperidin-2-ylbutoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCC1NCCCC1 HLGMPZWPOMLWJU-UHFFFAOYSA-N 0.000 claims description 2
- BGMJFKUYVNKUEB-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(4-piperidin-4-ylbutoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCC1CCNCC1 BGMJFKUYVNKUEB-UHFFFAOYSA-N 0.000 claims description 2
- JLWHIDAHZIWBRP-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(4-pyrrolidin-2-ylbutoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCC1NCCC1 JLWHIDAHZIWBRP-UHFFFAOYSA-N 0.000 claims description 2
- DLPIAKQSBKYCOM-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(4-pyrrolidin-3-ylbutoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCC1CNCC1 DLPIAKQSBKYCOM-UHFFFAOYSA-N 0.000 claims description 2
- USRUKVCBJBHGLZ-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(6-morpholin-4-ylhexoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCCCN1CCOCC1 USRUKVCBJBHGLZ-UHFFFAOYSA-N 0.000 claims description 2
- QREYAZBEIWDOOK-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(morpholin-4-ylmethoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCN1CCOCC1 QREYAZBEIWDOOK-UHFFFAOYSA-N 0.000 claims description 2
- KYVWHGIPSGWJDN-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[2-(4-phenylpiperazin-1-yl)ethoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCN1CCN(C=2C=CC=CC=2)CC1 KYVWHGIPSGWJDN-UHFFFAOYSA-N 0.000 claims description 2
- RXUHBRXELNKFMD-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[2-(naphthalen-1-ylamino)ethoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCNC1=CC=CC2=CC=CC=C12 RXUHBRXELNKFMD-UHFFFAOYSA-N 0.000 claims description 2
- LXLLPIVDJXERFP-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[2-(naphthalen-2-ylamino)ethoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCNC1=CC=C(C=CC=C2)C2=C1 LXLLPIVDJXERFP-UHFFFAOYSA-N 0.000 claims description 2
- OCHRELPUBODBJP-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[2-(propan-2-ylamino)ethoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(OCCNC(C)C)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 OCHRELPUBODBJP-UHFFFAOYSA-N 0.000 claims description 2
- DPURISRQLDJDIP-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[2-[4-(4-hydroxyphenyl)piperazin-1-yl]ethoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1N1CCN(CCOC=2C=CC(CC=3C4=CC=C(O)C=C4C=CC=3C=3C=CC(O)=CC=3)=CC=2)CC1 DPURISRQLDJDIP-UHFFFAOYSA-N 0.000 claims description 2
- VRBRXWDHSDNPLR-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[2-[4-(4-methoxyphenyl)piperazin-1-yl]ethoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(OC)=CC=C1N1CCN(CCOC=2C=CC(CC=3C4=CC=C(O)C=C4C=CC=3C=3C=CC(O)=CC=3)=CC=2)CC1 VRBRXWDHSDNPLR-UHFFFAOYSA-N 0.000 claims description 2
- KUWQWNDRLDWZPC-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[3-(4-phenylpiperazin-1-yl)propoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCN1CCN(C=2C=CC=CC=2)CC1 KUWQWNDRLDWZPC-UHFFFAOYSA-N 0.000 claims description 2
- GRHBTRBOGZNWRL-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[3-(naphthalen-1-ylamino)propoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCNC1=CC=CC2=CC=CC=C12 GRHBTRBOGZNWRL-UHFFFAOYSA-N 0.000 claims description 2
- PWOCOVNVRZWUIT-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[3-(naphthalen-2-ylamino)propoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCNC1=CC=C(C=CC=C2)C2=C1 PWOCOVNVRZWUIT-UHFFFAOYSA-N 0.000 claims description 2
- HIRQRKRWNGFIPN-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[3-(propan-2-ylamino)propoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(OCCCNC(C)C)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 HIRQRKRWNGFIPN-UHFFFAOYSA-N 0.000 claims description 2
- BUYTXPHTLIVTMG-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[3-[4-(4-hydroxyphenyl)piperazin-1-yl]propoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1N1CCN(CCCOC=2C=CC(CC=3C4=CC=C(O)C=C4C=CC=3C=3C=CC(O)=CC=3)=CC=2)CC1 BUYTXPHTLIVTMG-UHFFFAOYSA-N 0.000 claims description 2
- GDONNBLFTUFNAA-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[3-[4-(4-methoxyphenyl)piperazin-1-yl]propoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(OC)=CC=C1N1CCN(CCCOC=2C=CC(CC=3C4=CC=C(O)C=C4C=CC=3C=3C=CC(O)=CC=3)=CC=2)CC1 GDONNBLFTUFNAA-UHFFFAOYSA-N 0.000 claims description 2
- XABYHGSEOKXNMC-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[3-[4-(4-methylphenyl)piperazin-1-yl]propoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(C)=CC=C1N1CCN(CCCOC=2C=CC(CC=3C4=CC=C(O)C=C4C=CC=3C=3C=CC(O)=CC=3)=CC=2)CC1 XABYHGSEOKXNMC-UHFFFAOYSA-N 0.000 claims description 2
- JKZGLTIJQQHLNE-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[4-(4-phenylpiperazin-1-yl)butoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCN1CCN(C=2C=CC=CC=2)CC1 JKZGLTIJQQHLNE-UHFFFAOYSA-N 0.000 claims description 2
- KEMFMKAMLLNHCG-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[4-(naphthalen-1-ylamino)butoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCNC1=CC=CC2=CC=CC=C12 KEMFMKAMLLNHCG-UHFFFAOYSA-N 0.000 claims description 2
- AVVYVBJHDIQWLR-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[6-(methylamino)hexoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(OCCCCCCNC)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 AVVYVBJHDIQWLR-UHFFFAOYSA-N 0.000 claims description 2
- QKVDATFZLDIGTA-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[6-(propan-2-ylamino)hexoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(OCCCCCCNC(C)C)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 QKVDATFZLDIGTA-UHFFFAOYSA-N 0.000 claims description 2
- QGBZELQZHKOGDK-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[[4-(4-hydroxyphenyl)piperazin-1-yl]methoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1N1CCN(COC=2C=CC(CC=3C4=CC=C(O)C=C4C=CC=3C=3C=CC(O)=CC=3)=CC=2)CC1 QGBZELQZHKOGDK-UHFFFAOYSA-N 0.000 claims description 2
- BPKXZEIXVKVRSF-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[[4-(4-methoxyphenyl)piperazin-1-yl]methoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(OC)=CC=C1N1CCN(COC=2C=CC(CC=3C4=CC=C(O)C=C4C=CC=3C=3C=CC(O)=CC=3)=CC=2)CC1 BPKXZEIXVKVRSF-UHFFFAOYSA-N 0.000 claims description 2
- PTLSRIGSHUNLPP-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[[4-(4-methylphenyl)piperazin-1-yl]methoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(C)=CC=C1N1CCN(COC=2C=CC(CC=3C4=CC=C(O)C=C4C=CC=3C=3C=CC(O)=CC=3)=CC=2)CC1 PTLSRIGSHUNLPP-UHFFFAOYSA-N 0.000 claims description 2
- DFLWZOODWHDECI-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[methoxy-(4-piperidin-1-ylphenyl)methyl]naphthalen-2-ol Chemical compound C=1C=C(O)C=CC=1C=1C=CC2=CC(O)=CC=C2C=1C(OC)C(C=C1)=CC=C1N1CCCCC1 DFLWZOODWHDECI-UHFFFAOYSA-N 0.000 claims description 2
- XKBYXHTUOQSFIS-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[methoxy-(4-piperidin-2-ylphenyl)methyl]naphthalen-2-ol Chemical compound C=1C=C(O)C=CC=1C=1C=CC2=CC(O)=CC=C2C=1C(OC)C(C=C1)=CC=C1C1CCCCN1 XKBYXHTUOQSFIS-UHFFFAOYSA-N 0.000 claims description 2
- WKCIPQRMKRFRSE-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[methoxy-(4-piperidin-3-ylphenyl)methyl]naphthalen-2-ol Chemical compound C=1C=C(O)C=CC=1C=1C=CC2=CC(O)=CC=C2C=1C(OC)C(C=C1)=CC=C1C1CCCNC1 WKCIPQRMKRFRSE-UHFFFAOYSA-N 0.000 claims description 2
- PHZJSZOXIBPBMP-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[methoxy-(4-piperidin-4-ylphenyl)methyl]naphthalen-2-ol Chemical compound C=1C=C(O)C=CC=1C=1C=CC2=CC(O)=CC=C2C=1C(OC)C(C=C1)=CC=C1C1CCNCC1 PHZJSZOXIBPBMP-UHFFFAOYSA-N 0.000 claims description 2
- VYSBSRLNHKSDBH-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[methoxy-[4-(naphthalen-2-ylamino)phenyl]methyl]naphthalen-2-ol Chemical compound C=1C=C(NC=2C=C3C=CC=CC3=CC=2)C=CC=1C(OC)C(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 VYSBSRLNHKSDBH-UHFFFAOYSA-N 0.000 claims description 2
- XMTODSXRDGPJGF-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[methoxy-[4-(propan-2-ylamino)phenyl]methyl]naphthalen-2-ol Chemical compound C=1C=C(O)C=CC=1C=1C=CC2=CC(O)=CC=C2C=1C(OC)C1=CC=C(NC(C)C)C=C1 XMTODSXRDGPJGF-UHFFFAOYSA-N 0.000 claims description 2
- PXLSZEMJALXMPV-UHFFFAOYSA-N 8-[2-[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenoxy]ethyl]-1,3-dimethyl-5h-purine-2,6-dione Chemical compound N=1C2C(=O)N(C)C(=O)N(C)C2=NC=1CCOC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 PXLSZEMJALXMPV-UHFFFAOYSA-N 0.000 claims description 2
- VITHPDOOODUNRX-UHFFFAOYSA-N 8-[3-[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenoxy]propyl]-1,3-dimethyl-5h-purine-2,6-dione Chemical compound N=1C2C(=O)N(C)C(=O)N(C)C2=NC=1CCCOC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 VITHPDOOODUNRX-UHFFFAOYSA-N 0.000 claims description 2
- IEIHXZOEZNXHPL-UHFFFAOYSA-N C=1C=C(O)C=CC=1C=1C=CC2=CC(O)=CC=C2C=1C(OC)C(C=C1)=CC=C1N1CCCC1=O Chemical compound C=1C=C(O)C=CC=1C=1C=CC2=CC(O)=CC=C2C=1C(OC)C(C=C1)=CC=C1N1CCCC1=O IEIHXZOEZNXHPL-UHFFFAOYSA-N 0.000 claims description 2
- 125000005281 alkyl ureido group Chemical group 0.000 claims description 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims description 2
- MFICASSFAZRZJH-UHFFFAOYSA-N 1-[3-[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenoxy]propyl]pyrrolidin-2-one Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCN1C(=O)CCC1 MFICASSFAZRZJH-UHFFFAOYSA-N 0.000 claims 1
- SVWJTLFHLBDORN-UHFFFAOYSA-N 1-[4-[4-[2-[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenoxy]ethyl]piperazin-1-yl]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1N1CCN(CCOC=2C=CC(CC=3C4=CC=C(O)C=C4C=CC=3C=3C=CC(O)=CC=3)=CC=2)CC1 SVWJTLFHLBDORN-UHFFFAOYSA-N 0.000 claims 1
- GKROPDWTSISJLC-UHFFFAOYSA-N 1-[4-[4-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenoxy]methyl]piperazin-1-yl]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1N1CCN(COC=2C=CC(CC=3C4=CC=C(O)C=C4C=CC=3C=3C=CC(O)=CC=3)=CC=2)CC1 GKROPDWTSISJLC-UHFFFAOYSA-N 0.000 claims 1
- DQUBWDNQEBJJSI-UHFFFAOYSA-N 1-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-3-(4-methoxyphenyl)-1-methylurea Chemical compound C1=CC(OC)=CC=C1NC(=O)N(C)CC(C=C1)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 DQUBWDNQEBJJSI-UHFFFAOYSA-N 0.000 claims 1
- PAHTVCCGVJSJPT-UHFFFAOYSA-N 1-ethyl-1-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-3-(4-hydroxyphenyl)urea Chemical compound C=1C=C(O)C=CC=1NC(=O)N(CC)CC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 PAHTVCCGVJSJPT-UHFFFAOYSA-N 0.000 claims 1
- VIJZALRWHZPCOM-UHFFFAOYSA-N 1-ethyl-1-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]-3-(4-methoxyphenyl)urea Chemical compound C=1C=C(OC)C=CC=1NC(=O)N(CC)CC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 VIJZALRWHZPCOM-UHFFFAOYSA-N 0.000 claims 1
- LKPLDGMKWTZWAR-UHFFFAOYSA-N 5-[[4-(1h-azepin-2-yl)phenyl]-methoxymethyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C=1C=C(O)C=CC=1C=1C=CC2=CC(O)=CC=C2C=1C(OC)C(C=C1)=CC=C1C1=CC=CC=CN1 LKPLDGMKWTZWAR-UHFFFAOYSA-N 0.000 claims 1
- LAPZPNFMLGOSHB-UHFFFAOYSA-N 5-[[4-(1h-azepin-3-yl)phenyl]-methoxymethyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C=1C=C(O)C=CC=1C=1C=CC2=CC(O)=CC=C2C=1C(OC)C(C=C1)=CC=C1C1=CNC=CC=C1 LAPZPNFMLGOSHB-UHFFFAOYSA-N 0.000 claims 1
- XEYCOBUTXPBKBB-UHFFFAOYSA-N 5-[[4-(1h-azepin-4-yl)phenyl]-methoxymethyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C=1C=C(O)C=CC=1C=1C=CC2=CC(O)=CC=C2C=1C(OC)C(C=C1)=CC=C1C1=CC=CNC=C1 XEYCOBUTXPBKBB-UHFFFAOYSA-N 0.000 claims 1
- GPNDIKDNUBEFSH-UHFFFAOYSA-N 5-[[4-(azepin-1-yl)phenyl]-methoxymethyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C=1C=C(O)C=CC=1C=1C=CC2=CC(O)=CC=C2C=1C(OC)C(C=C1)=CC=C1N1C=CC=CC=C1 GPNDIKDNUBEFSH-UHFFFAOYSA-N 0.000 claims 1
- JOWQIXNADLOLRQ-UHFFFAOYSA-N 5-[[4-[(2,6-dimethylmorpholin-4-yl)methoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1C(C)OC(C)CN1COC(C=C1)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 JOWQIXNADLOLRQ-UHFFFAOYSA-N 0.000 claims 1
- BKKJHSZQNDQRMU-UHFFFAOYSA-N 5-[[4-[2-(1h-azepin-3-yl)ethoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCC1=CNC=CC=C1 BKKJHSZQNDQRMU-UHFFFAOYSA-N 0.000 claims 1
- DVWPJZMARFIXBJ-UHFFFAOYSA-N 5-[[4-[3-(1h-azepin-2-yl)propoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCC1=CC=CC=CN1 DVWPJZMARFIXBJ-UHFFFAOYSA-N 0.000 claims 1
- BOLBLKYYQHJCCC-UHFFFAOYSA-N 5-[[4-[6-(dibutylamino)hexoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(OCCCCCCN(CCCC)CCCC)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 BOLBLKYYQHJCCC-UHFFFAOYSA-N 0.000 claims 1
- VLPSZQYOSNZGEE-UHFFFAOYSA-N 5-[[4-[6-(diethylamino)hexoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(OCCCCCCN(CC)CC)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 VLPSZQYOSNZGEE-UHFFFAOYSA-N 0.000 claims 1
- YJICRAYJKOPFKS-UHFFFAOYSA-N 5-[[4-[6-(dimethylamino)hexoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(OCCCCCCN(C)C)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 YJICRAYJKOPFKS-UHFFFAOYSA-N 0.000 claims 1
- DLYQBEQKXUPPKQ-UHFFFAOYSA-N 5-[[4-[[di(propan-2-yl)amino]methoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(OCN(C(C)C)C(C)C)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 DLYQBEQKXUPPKQ-UHFFFAOYSA-N 0.000 claims 1
- YUTYZHAQIKXFKX-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(2-piperidin-3-ylethoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCC1CNCCC1 YUTYZHAQIKXFKX-UHFFFAOYSA-N 0.000 claims 1
- SHSYXTVZLRSKPR-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(3-pyrrolidin-2-ylpropoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCC1NCCC1 SHSYXTVZLRSKPR-UHFFFAOYSA-N 0.000 claims 1
- HEMFAANPDSHMFN-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(4-piperidin-1-ylbutoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCN1CCCCC1 HEMFAANPDSHMFN-UHFFFAOYSA-N 0.000 claims 1
- GQJMWJCIWVMSDF-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(4-piperidin-3-ylbutoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCC1CNCCC1 GQJMWJCIWVMSDF-UHFFFAOYSA-N 0.000 claims 1
- HQFLRUOXZWCMEH-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(4-pyrrolidin-1-ylbutoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCN1CCCC1 HQFLRUOXZWCMEH-UHFFFAOYSA-N 0.000 claims 1
- YECXZJHTIJVZQX-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(5-morpholin-4-ylpentoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCCN1CCOCC1 YECXZJHTIJVZQX-UHFFFAOYSA-N 0.000 claims 1
- XBNRRRPPZWFOEM-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[(1-methylpiperidin-2-yl)methoxy]phenyl]methyl]naphthalen-2-ol Chemical compound CN1CCCCC1COC(C=C1)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 XBNRRRPPZWFOEM-UHFFFAOYSA-N 0.000 claims 1
- RKWHGTXJWMASGD-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[(1-methylpiperidin-3-yl)methoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1N(C)CCCC1COC(C=C1)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 RKWHGTXJWMASGD-UHFFFAOYSA-N 0.000 claims 1
- LLGSOERLOYNRQG-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[2-[4-(4-methylphenyl)piperazin-1-yl]ethoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(C)=CC=C1N1CCN(CCOC=2C=CC(CC=3C4=CC=C(O)C=C4C=CC=3C=3C=CC(O)=CC=3)=CC=2)CC1 LLGSOERLOYNRQG-UHFFFAOYSA-N 0.000 claims 1
- IXYCBWOGCDMZEW-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[4-(naphthalen-2-ylamino)butoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCNC1=CC=C(C=CC=C2)C2=C1 IXYCBWOGCDMZEW-UHFFFAOYSA-N 0.000 claims 1
- HSVQWFJGQXNASM-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[methoxy-(4-pyrrolidin-1-ylphenyl)methyl]naphthalen-2-ol Chemical compound C=1C=C(O)C=CC=1C=1C=CC2=CC(O)=CC=C2C=1C(OC)C(C=C1)=CC=C1N1CCCC1 HSVQWFJGQXNASM-UHFFFAOYSA-N 0.000 claims 1
- BJIJMFCVWHWQNB-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[methoxy-(4-pyrrolidin-2-ylphenyl)methyl]naphthalen-2-ol Chemical compound C=1C=C(O)C=CC=1C=1C=CC2=CC(O)=CC=C2C=1C(OC)C(C=C1)=CC=C1C1CCCN1 BJIJMFCVWHWQNB-UHFFFAOYSA-N 0.000 claims 1
- KQMQDIUOBHICSQ-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[methoxy-(4-pyrrolidin-3-ylphenyl)methyl]naphthalen-2-ol Chemical compound C=1C=C(O)C=CC=1C=1C=CC2=CC(O)=CC=C2C=1C(OC)C(C=C1)=CC=C1C1CCNC1 KQMQDIUOBHICSQ-UHFFFAOYSA-N 0.000 claims 1
- OTMUPMVPGGSZOK-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[methoxy-[4-(methylamino)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(NC)=CC=C1C(OC)C1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 OTMUPMVPGGSZOK-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 abstract description 3
- 229940095743 selective estrogen receptor modulator Drugs 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 55
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 24
- 229920005989 resin Polymers 0.000 description 21
- 239000011347 resin Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 230000004663 cell proliferation Effects 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 7
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- WGYKZJWCGVVSQN-UHFFFAOYSA-N mono-n-propyl amine Natural products CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical group CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 239000012911 assay medium Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 229940046836 anti-estrogen Drugs 0.000 description 3
- 230000001833 anti-estrogenic effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000328 estrogen antagonist Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- BMYPVFBAFZKROJ-UHFFFAOYSA-N (4-hydroxyphenyl)-[6-methoxy-2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC(OC)=CC=C11)=C1C(=O)C1=CC=C(O)C=C1 BMYPVFBAFZKROJ-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- MCPFEGFVINDPMH-UHFFFAOYSA-N [2-(4-hydroxyphenyl)-6-(methoxymethoxy)naphthalen-1-yl]-[4-tri(propan-2-yl)silyloxyphenyl]methanone Chemical compound C=1C=C(O)C=CC=1C=1C=CC2=CC(OCOC)=CC=C2C=1C(=O)C1=CC=C(O[Si](C(C)C)(C(C)C)C(C)C)C=C1 MCPFEGFVINDPMH-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 229960003399 estrone Drugs 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229910000078 germane Inorganic materials 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 2
- 229940031826 phenolate Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000012508 resin bead Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- KUBUXIGBMZTQNS-UHFFFAOYSA-N 1-[4-[4-[2-[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenoxy]ethyl]piperazin-1-yl]phenyl]ethanone;dihydrochloride Chemical compound Cl.Cl.C1=CC(C(=O)C)=CC=C1N1CCN(CCOC=2C=CC(CC=3C4=CC=C(O)C=C4C=CC=3C=3C=CC(O)=CC=3)=CC=2)CC1 KUBUXIGBMZTQNS-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- HMGCGUWFPZVPEK-UHFFFAOYSA-N 2-naphthalen-2-ylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=C1 HMGCGUWFPZVPEK-UHFFFAOYSA-N 0.000 description 1
- BLULAKSNZLOYDY-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-ethyl-1-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenyl]methyl]urea Chemical compound C=1C=C(Cl)C=CC=1NC(=O)N(CC)CC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 BLULAKSNZLOYDY-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- ZZECGKLDFPBLBV-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-6-[4-(methoxymethoxy)phenyl]naphthalen-2-ol Chemical compound C1=CC(OCOC)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC1=CC=C(O)C=C1 ZZECGKLDFPBLBV-UHFFFAOYSA-N 0.000 description 1
- OIULNAWEXKGSJZ-UHFFFAOYSA-N 5-[[4-(1h-azepin-3-ylmethoxy)phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCC1=CNC=CC=C1 OIULNAWEXKGSJZ-UHFFFAOYSA-N 0.000 description 1
- VTONZJNJKKCUMU-UHFFFAOYSA-N 5-[[4-(1h-azepin-4-ylmethoxy)phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCC1=CC=CNC=C1 VTONZJNJKKCUMU-UHFFFAOYSA-N 0.000 description 1
- QXYHVQWXWOEAFP-UHFFFAOYSA-N 5-[[4-(3-azaspiro[5.5]undecan-3-ylmethoxy)phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCN1CCC2(CCCCC2)CC1 QXYHVQWXWOEAFP-UHFFFAOYSA-N 0.000 description 1
- HSYNPKXSLYYUIU-UHFFFAOYSA-N 5-[[4-(azepin-1-ylmethoxy)phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCN1C=CC=CC=C1 HSYNPKXSLYYUIU-UHFFFAOYSA-N 0.000 description 1
- XCJGFJJCUNADOM-UHFFFAOYSA-N 5-[[4-[2-(2,6-dimethylmorpholin-4-yl)ethoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol;hydrochloride Chemical compound Cl.C1C(C)OC(C)CN1CCOC(C=C1)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 XCJGFJJCUNADOM-UHFFFAOYSA-N 0.000 description 1
- UEMBZPQKRJSVAH-UHFFFAOYSA-N 5-[[4-[2-(3-azaspiro[5.5]undecan-3-yl)ethoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCN1CCC2(CCCCC2)CC1 UEMBZPQKRJSVAH-UHFFFAOYSA-N 0.000 description 1
- UILICMGUGRYIDB-UHFFFAOYSA-N 5-[[4-[2-(dibutylamino)ethoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol;hydrochloride Chemical compound Cl.C1=CC(OCCN(CCCC)CCCC)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 UILICMGUGRYIDB-UHFFFAOYSA-N 0.000 description 1
- FLOLXRFXKWEQGV-UHFFFAOYSA-N 5-[[4-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCN1CCN(C=2C=CC(Cl)=CC=2)CC1 FLOLXRFXKWEQGV-UHFFFAOYSA-N 0.000 description 1
- IFUSKDGILJTIMC-UHFFFAOYSA-N 5-[[4-[2-[di(propan-2-yl)amino]ethoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol;hydrochloride Chemical compound Cl.C1=CC(OCCN(C(C)C)C(C)C)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 IFUSKDGILJTIMC-UHFFFAOYSA-N 0.000 description 1
- CAZKZJGQCLOKKZ-UHFFFAOYSA-N 5-[[4-[3-(dibutylamino)propoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol;hydrochloride Chemical compound Cl.C1=CC(OCCCN(CCCC)CCCC)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 CAZKZJGQCLOKKZ-UHFFFAOYSA-N 0.000 description 1
- ZETKWIMIZOPUIJ-UHFFFAOYSA-N 5-[[4-[3-(diethylamino)propoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol;hydrochloride Chemical compound Cl.C1=CC(OCCCN(CC)CC)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 ZETKWIMIZOPUIJ-UHFFFAOYSA-N 0.000 description 1
- MSLJOUHDHMPTJS-UHFFFAOYSA-N 5-[[4-[4-(azepin-1-yl)butoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCCN1C=CC=CC=C1 MSLJOUHDHMPTJS-UHFFFAOYSA-N 0.000 description 1
- KHRFAWHTYFUBHH-UHFFFAOYSA-N 5-[[4-[6-(dibutylamino)hexoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol;hydrochloride Chemical compound Cl.C1=CC(OCCCCCCN(CCCC)CCCC)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 KHRFAWHTYFUBHH-UHFFFAOYSA-N 0.000 description 1
- YUTVVXMQMQKWJP-UHFFFAOYSA-N 5-[[4-[[4-(4-chlorophenyl)piperazin-1-yl]methoxy]phenyl]methyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCN1CCN(C=2C=CC(Cl)=CC=2)CC1 YUTVVXMQMQKWJP-UHFFFAOYSA-N 0.000 description 1
- XFNOPPDOROMFQX-UHFFFAOYSA-N 5-[[4-[di(propan-2-yl)amino]phenyl]-methoxymethyl]-6-(4-hydroxyphenyl)naphthalen-2-ol Chemical compound C=1C=C(O)C=CC=1C=1C=CC2=CC(O)=CC=C2C=1C(OC)C1=CC=C(N(C(C)C)C(C)C)C=C1 XFNOPPDOROMFQX-UHFFFAOYSA-N 0.000 description 1
- WABYVFZWFGBGHL-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(5-morpholin-4-ylheptoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1COCCN1C(CC)CCCCOC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 WABYVFZWFGBGHL-UHFFFAOYSA-N 0.000 description 1
- VKBXMMQINKGRTC-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(methylaminomethoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(OCNC)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 VKBXMMQINKGRTC-UHFFFAOYSA-N 0.000 description 1
- SAIYYZLNLQMYNZ-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(pyrrolidin-2-ylmethoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCC1NCCC1 SAIYYZLNLQMYNZ-UHFFFAOYSA-N 0.000 description 1
- CNUKNBCVXCOGSZ-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(pyrrolidin-3-ylmethoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCC1CNCC1 CNUKNBCVXCOGSZ-UHFFFAOYSA-N 0.000 description 1
- UJWUVBVGMZIHBN-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[(1-methylpiperidin-2-yl)methoxy]phenyl]methyl]naphthalen-2-ol;hydrochloride Chemical compound Cl.CN1CCCCC1COC(C=C1)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 UJWUVBVGMZIHBN-UHFFFAOYSA-N 0.000 description 1
- BWPZCPSAZPJKFB-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[(1-methylpiperidin-3-yl)methoxy]phenyl]methyl]naphthalen-2-ol;hydrochloride Chemical compound Cl.C1N(C)CCCC1COC(C=C1)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 BWPZCPSAZPJKFB-UHFFFAOYSA-N 0.000 description 1
- UELJXNDJNQHROF-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[(4-phenylpiperazin-1-yl)methoxy]phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCN1CCN(C=2C=CC=CC=2)CC1 UELJXNDJNQHROF-UHFFFAOYSA-N 0.000 description 1
- BLTWICKWKVIBGH-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-[3-(naphthalen-1-ylamino)propoxy]phenyl]methyl]naphthalen-2-ol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCCNC1=CC=CC2=CC=CC=C12 BLTWICKWKVIBGH-UHFFFAOYSA-N 0.000 description 1
- MHTYOUKYPGISBZ-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-tri(propan-2-yl)silyloxyphenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O[Si](C(C)C)(C(C)C)C(C)C)=CC=C1CC1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 MHTYOUKYPGISBZ-UHFFFAOYSA-N 0.000 description 1
- PJVPFDZXYWWOOQ-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[methoxy-[4-(1-methylpiperidin-3-yl)phenyl]methyl]naphthalen-2-ol Chemical compound C=1C=C(O)C=CC=1C=1C=CC2=CC(O)=CC=C2C=1C(OC)C(C=C1)=CC=C1C1CCCN(C)C1 PJVPFDZXYWWOOQ-UHFFFAOYSA-N 0.000 description 1
- SKPPZWVFPOQPOT-UHFFFAOYSA-N 6-(4-hydroxyphenyl)naphthalen-2-ol Chemical group C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1 SKPPZWVFPOQPOT-UHFFFAOYSA-N 0.000 description 1
- XCNQWPWFTPIXDX-UHFFFAOYSA-N 8-[4-[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenoxy]butyl]-1,3-dimethyl-5h-purine-2,6-dione Chemical compound N=1C2C(=O)N(C)C(=O)N(C)C2=NC=1CCCCOC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 XCNQWPWFTPIXDX-UHFFFAOYSA-N 0.000 description 1
- LFSDSGWKPLEMQY-UHFFFAOYSA-N 8-[[4-[[6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]methyl]phenoxy]methyl]-1,3-dimethyl-5h-purine-2,6-dione Chemical compound N=1C2C(=O)N(C)C(=O)N(C)C2=NC=1COC(C=C1)=CC=C1CC(C1=CC=C(O)C=C1C=C1)=C1C1=CC=C(O)C=C1 LFSDSGWKPLEMQY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 238000006959 Williamson synthesis reaction Methods 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- DEEHQCPWQCDILY-UHFFFAOYSA-N [6-hydroxy-2-(4-hydroxyphenyl)naphthalen-1-yl]-[4-tri(propan-2-yl)silyloxyphenyl]methanone Chemical compound C1=CC(O[Si](C(C)C)(C(C)C)C(C)C)=CC=C1C(=O)C1=C(C=2C=CC(O)=CC=2)C=CC2=CC(O)=CC=C12 DEEHQCPWQCDILY-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000001038 ionspray mass spectrometry Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229940063238 premarin Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006009 resin backbone Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LHJCZOXMCGQVDQ-UHFFFAOYSA-N tri(propan-2-yl)silyl trifluoromethanesulfonate Chemical compound CC(C)[Si](C(C)C)(C(C)C)OS(=O)(=O)C(F)(F)F LHJCZOXMCGQVDQ-UHFFFAOYSA-N 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
Abstract
A class of substituted benzylnaphthylene compounds of structure (1) where R1 and R2 are independently hydrogen, alkyl of one to six carbon atoms, acyl of two to six carbon atoms, or phenacyl; X is -(CH2)1-6; Y is absent or is selected from 1,4-piperazinylene; ureido; N-(lower alkyl)ureido; N'-(lower alkyl)ureido; or N,N'-(di-lower alkyl)ureido; and Z is 1-, 2- or 3pyrrolidinyl; 1-, 2-, or 3-¢1-(lower alkyl)pyrrolidinyl!; 1-, 2-, 3- or 4piperidinyl; 1-, 2-, 3- or 4-¢1-lower alkyl)piperidinyl!; N,N-dialkyl; 1azepinyl; 1- or 2-naphthylamino, 4-morpholinyl, dimethyl-4-morpholinyl, 3azaspiro¢5.5!undecan-3-yl; pyrrolidinon-1-yl; unsubstituted phenyl; or phenyl substituted with acyl of two to four carbon atoms, alkyl of one to four carbon atoms, halo, or alkoxy of one to four carbon atoms; with the proviso that n is not 2 or 3 when Z is 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, N,N-dimethylamino or N,N-diethylamino; are selective estrogen receptor modulators useful in the prophylaxis or treatment of breast cancer.
Description
1-[4-(Substituted alkoxy)benzyllnaDhthalene Compounds Having 8strogen Inhibitory Activity Technical Field The present invention relates to organic compounds having pharmacological activity, to compositions containing the compounds, and to a medical method of treatment.
More particularly, the present invention concerns a class of 1-[4-(substituted alkoxy)benzyl]naphthalene io compounds having estrogenic activity, to pharmaceutical compositions containing the compounds and to a method of treating or inhibiting cancer of the breast or uterus.
Background of the Invention Estrogen is a generic term for estrus-producing steroid compounds. Within the "estrogen group" are the traditional steroids such as 173-estradiol and estrone (the major estrogens in humans), as well as various metabolites such as the estratriols, sulfates and glucuronides of estradiol and 2o estrone. Also, germane to human medicine, are the steroidal equine estrogens such as the equilins, in that they are administered to humans in preparations, such as Premarin=".
Also, certain compounds known as "anti-estrogens", e.g., tamoxifen, clomiphene, and nafoxidene, demonstrate varying degrees of estrogen agonist properties in some tissues;
however they act to antagonize the natural estrogens and their function in other tissues.
Recently, these uanti-estrogens" have been categorized into three different types depending on their degree and mix of estrogen agonist/antagonist properties which is based on their ability to freeze estrogen receptors in different conformational states, cf. D. P. McDonnell, et al., Molecular Endocrinology, 9(6): 659-669 (1995). Most germane are the type II anti-estrogens of which compounds of the current invention belong.
Estrogens as biologically active molecules exert their properties by binding to an intracellular receptor. After the receptor and bound ligand are transported to the nucleus of a cell, the complex exerts its effect by binding to certain recognition sites on DNA and allowing certain genes to be expressed. This binding to the receptor and regulation is not completely understood at this time;
1o however, it appears to be crucial to the varying degree of agonistic and antagonistic properties of a molecule. Thus, certain types of so-called "anti-estrogens" allow agonist activity in some tissues, but are antagonists in others.
Hence, the term, "selective estrogen receptor modulators ~5 (SERMs)" has been proposed to describe these molecules, especially the type II, of which the compounds of the present invention are members.
Estrogen has long been classified as "the female sex hormone" and a voluminous literature describes its activity 2o as such. However, in recent years, research has shown that estrogens have many other homeostatic functions, other than those related to female reproduction and function of sex tissues. Indeed, it has been shown that males possess estrogen receptors and DNA recognition sites and possess the 25 ability to produce estrogens and many tissues, such as those involved in the cardiovascular system. The exact nature of the effects of estrogens in both men and women, outside the productive aspects, are only beginning to be explored and are currently poorly understood.
3o The majority of the documented activities of the estrogens have been derived from studies in women, since most women suffer from the most obvious effects of estrogen, mainly due to menopause and estrogen dependent cancers. The clinical pathologies associated with estrogen levels and 35 their subsequent function, can be categorized into two main types, i.e., those which are due to a deprivation or lack of _3-estrogen and those which are due to an aberrant physiological response to existing estrogen in estrogen sensitive tissues. SERMS, especially those of type II, have the property of being estrogen agonists in those cases where estrogen deprivation is a cause of pathology (mainly in non-sex related tissues) and simultaneously being antagonists of the pathologies caused by abnormal responses to endogenous estrogen (in sex related tissues).
Thus, SERMS of the type II have the potential to to effectively treat a variety of estrogen dependent pathological conditions. This dual effect is an intrinsic and unique property of the molecules of the present invention.
Summary of the Invention In its principal embodiment, the present invention provides a selective estrogen modulating compound of structure 1:
,Y
Z
or a pharmaceutically acceptable salt thereof where R1 and R2 are independently selected from hydrogen, alkyl of one to six carbon atoms, acyl of two to six carbon atoms, and phenacyl.
The group designated X is -(CH2)n where n is an integer of one to 6, inclusive.
Y is absent or is selected from the group consisting of 1,4-piperazinylene; ureido; N-(lower alkyl)ureido; N'-(lower alkyl)ureido; and N, N'-(di-lower alkyl ureido.
3o The substitutent Z is selected from the group consisting of 1-, 2- or 3-pyrrolidinyl; 1-, 2-, or 3-[1-(lower alkyl)pyrrolidinyl]; 1- 2-,3- or 4-piperidinyl; 1-, 2-, 3- or 4-[1-lower alkyl)piperidinyl]; N,N-dialkyl in which the alkyl groups are independently from one to four carbon atoms; 1-azepinyl; 1- or 2-naphthylamino;
morpholinyl; dimethyl-4-morpholinyl; 3-azaspiro[5.5]undecan-3-yl; pyrrolidinon-1-yl; unsubstituted phenyl; and phenyl substituted with one or two groups independently selected from acyl of two to four carbon atoms, alkyl of one to four carbon atoms, halo, and alkoxy of one to four carbon atoms.
io All of the above definitions are with the proviso that n is not 2 or 3 when Z is 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, N,N-dimethylamino or N,N-diethyl-amino.
In a second embodiment, the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound as defined above in combination with a pharmaceutically acceptable carrier.
In another embodiment, the present invention comprises a method of treating or inhibiting estrogen-dependent 2o cancers in women, particularly cancer of the breast and uterus, comprising administering to a woman in need of such treatment an effective amount of a compound as defined above.
Detailed Description As used throughout this specification and the appended claims, the following terms have the meanings ascribed to them.
"Alkyl of one to six carbon atoms" means a univalent 3o radical derived by the removal~of one hydrogen atom from methane, ethane, or a straight or branched hydrocarbon of three to six carbon atoms and is typified by methyl, ethyl, n- or iso-propyl, n-, sec- iso- or tent-butyl, n-pentyl, 2-methylbutyl, n-hexyl, 2-methylpentyl, 2,3-dimethylbutyl, and the like.
"Acyl" denotes an alkyl group as defined above, attached to the parent molecular moiety through a carbonyl group.
"Lower alkyl" denotes an alkyl group as defined above containing one to four carbon atoms.
The term "alkoxy" refers to an alkyl group, as defined above, attached to the parent molecular moiety through an 1o oxygen atom.
The term "1,4-piperazinylene" denotes a divalent radical of the structure:
n -N N
U.
and the term "ureido" means the divalent radical represented by the structure H H
~N~N~
O
The term "N-(lower alkyl)ureido", as used herein, means a ureido group in which the lower alkyl group is attached to the nitrogen nearest the group denoted "X" in structure 1 above, thus:
H alkyl Z.N~N.X~
fIO
and "N'-(lower alkyl)ureido" means a ureido group in which the lower alkyl group is attached to the nitrogen nearest the group denoted "Z" in structure I above, thus:
*rB
~Ikyl H
Z.N~N.X~
IIO
Compounds contemplated as falling within the scope of the present invention include, but are not limited to, the following representative examples.
Compounds of the present invention in which Y is absent, and Z is alkyl or dialkyl include:
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-methylamino)methoxy-benzyl]naphthalene;
io 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N,N-dimethylamino)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-isopropylamino)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N,N-diisopropylamino)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(N-isopropylamino)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N-isopropylamino)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N,N-diisopropyl-amino)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N-butylamino)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N,N-dibutylamino)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N-methylamino)-hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N,N-dimethylamino)-3o hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N-ethylamino)-hexoxy)benzyl]naphthalene;
WO 99!07377 PCT/US98/16065 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(5-(N,N-diethylamino)-hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N-isopropylamino)-hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N,N-diisopropyl-amino)hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N-butylylamino)-hexoxy)benzyl]naphthalene; and 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N,N-dibutylamino)-1o hexoxy)benzyl]naphthalene.
Examples of compounds of the present invention in which X is alkylene, Y is absent, and Z is pyrrolidinyl include:
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(pyrrolidin-1-yl)methoxy-benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(pyrrolidin-2-yl)methoxy-benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(pyrrolidin-3-yl)methoxy-benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(pyrrolidin-2-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(pyrrolidin-3-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(3-(pyrrolidin-2-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(pyrrolidin-3-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(4-(pyrrolidin-1-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(pyrrolidin-2-yl)-butoxy)benzyl]naphthalene; and 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(pyrrolidin-3-yl)-butoxy)benzyl]naphthalene.
_g_ Compounds of the present invention in which Y is absent, and Z is pyrrolidinon-1-yl include:
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(pyrrolidinon-1-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(pyrrolidinon-1-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(pyrrolidinon-1-yl)-1o propoxy)benzyl]naphthalene; and 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(pyrrolidinon-1-yl)-butoxy)benzyl]naphthalene.
Compounds of the present invention in which Y is absent, and Z is piperidinyl include:
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(piperidin-1-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(piperidin-2-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-methylpiperidin-2-yl)-2o methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(piperidin-3-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-methylpiperidin-3-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(piperidin-4-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(piperidin-2-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(piperidin-3-yl)-3o ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(piperidin-4-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(piperidin-2-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(piperidin-3-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(piperidin-4-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(4-(piperidin-1-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(piperidin-2-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(piperidin-3-yl)-to butoxy)benzyl]naphthalene; and 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(piperidin-4-yl)-butoxy)benzyl]naphthalene.
Compounds of the present invention in which Y is absent and Z is azepinyl include:
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(azepin-1-yl)methoxy-benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(azepin-2-yl)methoxy-2o benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(azepin-3-yl)methoxy-benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(azepin-4-yl)methoxy-benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(azepin-2-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(2-(azepin-3-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(azepin-2-yl)-3o propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(azepin-3-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(azepin-1-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(azepin-2-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(azepin-3-yl)-butoxy)benzyl]naphthalene; and 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(azepin-4-yl)-butoxy)benzyl]naphthalene.
Compounds of the present invention in which Y is absent and Z is 4-morpholinyl include:
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(morpholin-4-yl-methoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[(4-(4-(morpholin-4-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(5-(morpholin-4-yl)-heptoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(morpholin-4-yl) hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2,6-dimethylmorpholin-4-2o ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(2,6-dimethyl-morpholin-4-yl)ethoxy)benzyl]naphthalene; and 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(2,6-dimethyl-morpholin-4-yl)propoxy)benzyl]naphthalene.
Compounds of the present invention in which Y is absent and Z is 1- or 2-aminonaphthyl include:
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(naphth-1-ylamino) 3o methoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(naphth-1-ylamino)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(naphth-1-ylamino)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(naphth-1-ylamino)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(naphth-2-ylamino)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(naphth-2-ylamino)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(naphth-2-ylamino)-propoxy)benzyl]naphthalene; and 5-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(naphth-2-ylamino)-io butoxy)benzyl]naphthalene.
Compounds of the present invention in which Y is absent and Z is 3-azaspiro[5.5]undec-3-yl include:
t5 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-azaspiro[5.5]undec-3-yl)methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(3-azaspiro[5.5]undec-3-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(3-azaspiro[5.5]undec-20 3-yl)propoxy)benzyl]naphthalene; and 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(3-azaspiro[5.5]undec-3-yl)butoxy)benzyl]naphthalene.
Compounds of the present invention in which Y is absent 25 and Z is 2,3,5,6-tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl include:
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2,3,5,6-tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl)methoxybenzyl]-naphthalene;
30 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(2,3,5,6-tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl)ethoxy)benzyl]-naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(2,3,5,6-tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl)propoxy)benzyl]-naphthalene; and 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(2,3,5,6-tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl)butoxy)benzyl]-naphthalene.
Compounds of the present invention in which Y is 1,4-piperazinylene and Z is phenyl or substituted phenyl 1o include:
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-phenylpiperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-phenylpiperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-phenylpiperazin-1-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-phenylpiperazin-1-yl)butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-methylphenyl) piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-chlorophenyl)-piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-hydroxyphenyl)-piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-methoxyphenyl)-piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(4-(4-acetylphenyl)-piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(2-(4-(4-methylphenyl)-piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-(4-chlorophenyl)-piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-(4-hydroxyphenyl)-piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-(4-methoxyphenyl)-piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(2-(4-(4-acetylphenyl)-piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-methylphenyl)-piperazin-1-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-chlorophenyl)-piperazin-1-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-hydroxyphenyl)-piperazin-1-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-methoxyphenyl)-piperazin-1-yl)propoxy)benzyl]naphthalene; and t5 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-acetylphenyl)-piperazin-1-yl)propoxy)benzyl]naphthalene.
Compounds of the present invention in which Y is ureido and Z is phenyl or substituted phenyl include:
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-phenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenyl)ethyl]-N'-phenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-phenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-4-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-4-chlorophenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-4-hydroxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-4-methoxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-3-chloro-2-methylphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl) phenyl)ethyl]-N'-4-methylphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenyl)ethyl]-N'-4-chlorophenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenyl)ethyl]-N'-4-hydroxyphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenyl)ethyl]-N'-4-methoxyphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl) phenyl)ethyl]-N'-3-chloro-2-methylphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-4-methylphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-phenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-4-chlorophenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-4-hydroxyphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-4-methoxyphenyl urea; and N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-3-chloro-2-methylphenyl urea.
Compounds of the present invention where Z is N-alkylureido and Z is phenyl or substituted phenyl include:
3o N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1 ylmethyl)phenylmethyl]-N'-phenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-phenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-2-ylmethyl)phenylpropyl]-N'-phenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-methylphenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-chlorophenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-hydroxyphenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-1o ylmethyl)phenylmethyl]-N'-4-methoxyphenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-3-chloro-2-methylphenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-methylphenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-chlorophenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-hydroxyphenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1 2o ylmethyl)phenyl)ethyl]-N'-4-methoxyphenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-3-chloro-2-methylphenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-methyiphenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-phenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-chlorophenyl urea;
3o N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-hydroxyphenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-methoxyphenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-3-chloro-2-methylphenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-methylphenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-chlorophenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyi)phenylmethyl]-N'-4-hydroxyphenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-1o ylmethyl)phenylmethyl]-N'-4-methoxyphenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-3-chloro-2-methylphenyl urea;
N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-methylphenyl urea;
t5 N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-chlorophenyl urea;
N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-hydroxyphenyl urea;
N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-2o ylmethyl)phenyl)ethyl]-N'-4-methoxyphenyl urea;
N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-3-chloro-2-methylphenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-methylphenyl urea;
25 N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-phenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1 ylmethyl)phenylpropyl]-N'-4-chlorophenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-3o ylmethyl)phenylpropyl]-N'-4-hydroxyphenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-methoxyphenyl urea; and N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyi)phenylpropyl]-N'-3-chloro-2-methylphenyl urea.
Examples of compounds of the present invention where Y
is N'-alkylureido and Z is phenyl or substituted phenyl include:
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-phenyl urea;
N-[4-(2-(&-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenyl)ethyl]-N'-methyl-N'-phenyl urea;
1o N-(4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-ethyl-N'-phenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-4-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-4-chlorophenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-4-hydroxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-4-methoxyphenyl urea;
2o N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-3-chloro-2-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-ethyl-N'-4-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-ethyl-N'-4-chlorophenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-ethyl-N'-4-hydroxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-3o phenylmethyl]-N'-ethyl-N'-4-methoxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-ethyl-N'-3-chloro-2-methylphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenyl)ethyl]-N'-methyl-N'-4-methylphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl) phenyl)ethyl]-N'-methyl-N'-4-chlorophenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl) phenyl)ethyl]-N'-methyl-N'-4-hydroxyphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenyl)ethyl]-N'-methyl-N'-4-methoxyphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenyl)ethyl]-N'-methyl-N'-3-chloro-2-methylphenyl urea;
1o N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-ethyl-N'-4-methylphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl) phenylpropyl]-N'-ethyl-N'-phenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-~5 phenylpropyl]-N'-ethyl-N'-4-chlorophenyl urea;
N-(4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'ethyl-N'-4-hydroxyphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-ethyl-N-4-methoxyphenyl urea; and 20 N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-ethyl-N'-3-chloro-2-methylphenyl urea.
The compounds of the present invention are synthesized by standard methods known to practitioners of the organic 25 chemical arts using starting materials which are either commercially available or are prepared by methods disclosed in the chemical literature.
In the present invention, the compounds were prepared by methods of parallel combinatorial synthesis using the 3o process depicted in Reaction Scheme 1. Thus, in each Example presented below, only small amounts of each compound were prepared for purposes of pharmacological evaluation.
It will be understood by chemists skilled in the organic chemical art that, if required, larger quantities of each compound disclosed within this specification can be made using the reactions and reagents taught for the combinatorial processes disclosed.
Referring to Reaction Scheme 1, the starting material for the process, [3,4-dihydro-6-methoxy-2-(4-methoxyphenyl)-1-naphthalenyl](4-hydroxyphenyl)methanone, 2, is prepared according to the method disclosed by Jones, et al., J. Med.
Chem., 35: 931-938 (1992). The free alcohol function of compound 2 is converted to the triisopropylsiloxyl residue of compound 3 by reaction of 2 with triisopropylsiloxyl triflate (Aldrich Chemical Co., Milwaukee, WI, USA). The reaction is generally carried out by the method of E. J.
Corey, et al., Tetrahedron Lett., 22: 3455 (1981) in dichloromethane in the presence of an acid scavenger such as diisopropylethylamine. The methoxy groups of compound 3 are next removed by reaction of 3 with aluminum chloride and ethanethiol using the method of Node, et al, Chem. Lett., 97 (1979). Subsequent reaction of 3 with lithium aluminum hydride reduces the linking carbonyl group and concomitantly 2o aromatizes the tetrahydronaphthyl ring system of 3 to the naphthyl ring system of 4 after acid treatment.
Compound 4 is next reacted with methoxymethyl chloride (MOM-C1) using the methods disclosed by G. Stork, et al., J.
Am. Chem. Soc., 99: 1275 (1977). This process produces a mixture of isomers 5a and 5b which are carried forward without separation.
Reactioa Scheme 1 HO TIPSO
TI PSOTf 1. AICi3 / EtSH
2. LAH
3. HCI
TIPSO
OH
MOMCI HO ~ MOMCI
TlPSO TIPSO
OMOM OH
HO MOMO~
CI
Resin CI Resin O O
TIPSO
Resin O
O
MOMO_ v v TBAF TBAF
HO HO
OMOM Resin O
O
O~
Resin ~ MOMO
l~
The mixture of isomers, 5a and 5b are next reacted with the acid chloride form of the resin to attach the both triisopropylsilyl protected isomers to the resin backbone.
Reaction Scheme 1 (continued) HO
HO
OMOM Resin O
O ~ O
Resin O 1~ MOMO
.X. .Z .X. .Z
HO Y HO Y I~ ~l~p ph )3 't~ N.p~ph)a O~S~O
S
O % ~ p Z.Y,X.O
Z.Y.X.O O
OMOM Resin O
O MOMO
Resin O $~ $
n-PrNH2 n-PrNH2 Z.Y.X.O Z.Y.X.O
OMOM OH
HO ~ MOMO
1;3!
Z.Y.X.O
OR' R' O'~
1~
Z.Y.X.O
OH
HO~
This process is carried out in an aprotic organic solvent, such as dichloromethane, by reacting the acid chloride form of the resin with the protected alcohol mixture in the presence of an amine acid scavenger such as triethylamine.
The reaction is typically carried out by gently stirring the mixture (to avoid mechanical breakage of the resin beads) at room temperature for a period of from 8 to 24 hours. The loaded resin, 6a and 6b is then collected by filtration and washed free of the unreacted substrate.
1o Deprotection of the mixture, 6a and 6b with tetra-n-butylammonium fluoride in tetrahydrofuran, using the method of S. V. Frye, Tetrahedron Lett., 27: 3223 (1986) removes the triisopropylsilyl protecting group and yields the mixture of resin-bound, deprotected isomers 7a and 7b.
i5 The mixture of resin-bound intermediates, 7a and 7b, is next derivatized at the free hydroxyl position by reaction of the free phenolic functions of 7a and 7b with a commercially available alcohol, ZYX-OH, under Mitsunobu conditions (see J. L. Castro, et al., J. Org. Chem., 59:
20 2289-2291 (1994). These couplings were carried out by combinatorial chemistry means by placing 30 mg (0.04 mmol of the mixture of resin-bound phenolic substrates 7a and 7b in each well of a 96-well plate, together with 0.4 mL of a 1 molar solution of the particular alcohol in toluene. To 25 each well was also added 0.4 mL of a 1 molar suspension of a betaine coupling reagent having the structure N. .N-PPh 0 S..O s The derivatized, resin-bound mixture of intermediates 8a and 8b are then subjected to cleavage by reaction with 3o n-propylamine at room temperature for a period of about 24 hours to produce the methoxymethyl protected compound mixture 9a and 9b.
In the instances where the desired end-product is a 6-hydroxy-2-(4-hydroxyphenyl)naphthalene of structure la where both R1 and R2 are hydrogen, the methoxymethyl protecting groups of 9a and 9b are removed by reaction with acid, typically a trace of 4 molar hydrochloric acid in dioxane, according to the method of J. Auerbach, et al., J. Chem.
Soc., Chem. Commun., 298 (1974).
The compounds of structure 1b in which the groups designated R1 are both the same can be prepared directly from la by ether-forming or esterification reactions well known in the art.
Referring to Reaction Scheme 2, in the instance where t5 the desired end product of the reaction is a compound of structure le in which R1 is alkyl, alkylcarbonyl, or phenylcarbonyl, compound mixture 9a and 9b is first separated by conventional means such as column chromatography. Compound 9a is then reacted under basic 2o conditions to produce the desired methoxymethyl protected ether or ester, lc, followed by cleavage of the methoxymethyl protecting group to yield the desired product, 1e.
In a similar fashion, if the desired end-product is a 25 compound of structure if where R2 is is alkyl, alkylcarbonyl, or phenylcarbonyl, compound 9b (separated from its isomer) is reacted under basic conditions to produce the desired methoxymethyl protected ether or ester, 1e, followed by cleavage of the methoxymethyl protecting 30 group to yield the desired product, lf.
Specifically, when is it desired that R1 be alkyl, compound 9 is reacted with a suitable base such as potassium Reaction Scheaae 2 Z.Y.X.O Z.Y.X.O
' OMOM OH
HO ~ MOMO
Z.Y.X.O Z.Y.x.O
R'O MOMO~~~
1~ 1~
Z.Y.X.O Z.Y.X.O
OH OR
R'O'B HO
le Z.Y,X.O Z.Y,X.O
R'O R'O
15~
carbonate to yield the corresponding phenolate which is then reacted under typical Williamson ether synthesis conditions with an alkyl chloride to produce the alkyl ether, lb. In a similar manner, when it is desired that R1 be alkoxycarbonyl, the base-generated phenolate of 9 is reacted with the desired acid chloride in the presence of an acid scavenger such as triethylamine to produce lb. In those instances where R1 and R2 are the same in the desired end-product, the diethers or diesters are prepared by conventional means from compound la (cf. Reaction Scheme 1).
If, in the desired end-product, R1 and R2 are different and other than hydrogen, the free hydroxyl functions of intermediates la or 1f are converted by convention means to the desired ether, acyl, or phenacyl group.
Certain compounds falling within the scope of the present invention possess one or more chiral centers and are thus capable of existing in two or more enantiomeric or diastereomeric forms. The present invention contemplates all individual enantiomers of such compounds as well as mixtures thereof in cluding the racemic mixtures.
The individual enantiomers are obtained by methods well known in the art such as the separation by recrystallization of diastereomers formed by reacting racemic mixtures of the enantiomers with a resolved enantiomeric acid. The desired enantiomer is then regenerated from the diastereomeric salt by reaction with base. Alternatively, the individual enantiomers are separated from mixtures by means of standard 2o chromatigraphic separation techniques using "chiral columns," i.e. commercially available chromatographic columns charged with a chiral adsorbant.
The compounds~of the present invention in which the substituent Z contains a basic nitrogen atom are capable of forming acid addition salts with a wide variety of organic and inorganic acids and include the physiologically acceptable salts which are often used in the pharmaceutical formulation art. The present invention contemplates within its scope pharmaceutically acceptable acid addition salts of 3o compound of structure 1.
The term °pharmaceutically acceptable salts" denotes salts of the type described by S. M. Berge, et al., J.
Pharm. Sci., 66(1): 1-19 (1977) and includes typical inorganic acids such as hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, hypophosphoric and the like. Salts derived from organic acids, such as aliphatic mono and dicarboxylic acids, phenyl substituted alkanoic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, may also be used.
Such pharmaceutically acceptable salts include the acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, 1o hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, hydrobromide, isobutyrate, phenylbutyrate, i3-hydroxybutyrate, butyne-1,4-dioate, hexyne-1,4-dioate, caprate, caprylate, hydrochloride, cinnamate, citrate, formate, fumarate, glycollate, heptanoate, hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, teraphthalate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate, benzene-sulfonate, p-bromophenylsulfonate, chlorobenzenesulfonate, ethanesulfonate, 2-hydroxy-ethanesulfonate, methanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate, xylenesulfonate, tartarate, salts and the like.
A preferred salt of compounds of the present invention is the hydrochloride salt.
The pharmaceutically acceptable acid addition salts are 3o typically formed by reacting a compound of formula I with one equivalent (or slight excess) of acid. The reactants are generally combined in a mutual solvent such as diethyl ether, methanol, ethanol, or aqueous alcohol. The salt normally precipitates out of solution within about one hour to 10 days and can be isolated by filtration or the solvent can be stripped off by conventional means.
The pharmaceutically acceptable salts generally have enhanced solubility characteristics compared with the compound from which they are derived, and thus are often more amenable to formulation in solution or emulsion formulations.
For administration to a patient, the compounds of the present invention are formulated into a pharmaceutical formulation using standard practices well known in the formulation art. The present invention also provides pharmaceutical compositions which comprise compounds of the present invention formulated together with one or more non-toxic pharmaceutically acceptable carriers and/or excipients.
The formulations may be specially formulated for oral administration in solid or liquid form, for parenteral injection, or for rectal or vaginal administration by means of a suppository.
2o The pharmaceutical compositions of this invention can be administered to humans and other mammals orally, rectally, intravaginally, parenterally, topically (by means of powders, ointments, creams, or drops), bucally or sublingually, or as an oral or nasal spray. The term "parenteral administration" refers herein to modes of administration which include intravenous, intramuscular, intraperitoneal, instrasternal, subcutaneous, or intraarticular injection or infusion.
Pharmaceutical compositions of this invention for parenteral administration comprise sterile aqueous or non-aqueous solutions, dispersions, suspensions, or emulsions, as well as sterile powders which are reconstituted immediately prior to use into sterile solutions or suspensions. Examples of suitable sterile aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, physiological saline solution, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol), and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity is maintained, for example, by the use of coating materials such as lecithin, by the maintenance of proper particle size in the case of dispersions and suspensions, and by the use of surfactants.
1o Parenteral compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms is ensured by the inclusion of antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of injectable formulations may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and 2o gelatin.
In some cases, in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug following subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension or crystalline or amorphous material of low water solubility or by dissolving or suspending the drug in an oil vehicle. In the case of the subcutaneous or intramuscular injection of a suspension containing a form of the drug with low water solubility, the rate of absorption of the drug depends upon 3o its rate of dissolution.
Injectable "depot" formulations of the compounds of this invention are made by forming microencapsulated matrices of the drug in biodegradable polymers such as poly(lactic acid), poly(glycolic acid), copolymers of lactic and glycolic acid, poly (orthoesters), and poly (anhydrides) these materials which are described in the art.
Depending upon the ratio of drug to polymer and the characteristics of the particular polymer employed, the rate of drug release can be controlled.
Injectable formulations are sterilized, for example, by filtration through bacterial-retaining filters, or by presterilization of the components of the mixture prior to their admixture, either at the time of manufacture or just to prior to administration (as in the example of a dual chamber syringe package).
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active component is mixed with at t5 least one inert, pharmaceutically acceptable carrier such as sodium citrate, or dicalcium phosphate, and/or (a) fillers or extenders such as starches, lactose, glucose, mannitol, and silicic acid, (b) binding agents such as carboxymethylcellulose, alginates, gelatin, 2o poly(vinylpyrrolidine), sucrose and acacia, D humectants such as glycerol, (d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, silicates and sodium carbonate, (e) solution retarding agents such as paraffin, (f) absorption accelerating agents 25 such as quaternary ammonium compounds, (g) wetting agents such as cetyl alcohol and glycerin monostearate, (h) absorbents such as kaolin and bentonite clay, and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols), sodium lauryl 3o sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also contain buffering agents.
Solid compositions of a similar type may also comprise the fill in soft or hard gelatin capsules using excipients such as lactose as well as high molecular weight polyethylene glycols) and the like.
Solid dosage forms such as tablets, dragees, capsules, pills and granules can also be prepared with coatings or shells such as enteric coatings or other coatings well known in the pharmaceutical formulating art. The coatings may contain opacifying agents or agents which release the active ingredients) in a particular part of the digestive tract, as for example, acid soluble coatings for release of the 1o active ingredients) in the stomach, or base soluble coatings for release of the active ingredients) in the intestinal tract.
The active ingredients) may also be microencapsulated in a sustained-release coating, with the microcapsules being made part of a pill of capsule formulation.
Liquid dosage forms for oral administration of the compounds of this invention include solution, emulsions, suspensions, syrups and elixirs. In addition to the active components, liquid formulations may include inert diluents 2o commonly used in the art such as water or other pharmaceutically acceptable solvents, solubilizing agents and emulsifiers such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, ground nut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols), fatty acid esters of sorbitol, and mixtures thereof.
Besides inert diluents, the liquid oral formulations 3o may also include adjuvants such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.
Liquid suspension, in addition to the active ingredients) may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite clay, agar-agar, and tragacanth, and mixtures thereof.
Compositions for rectal or intravaginal administration are prepared by mixing one or more compounds of the present invention with suitable non-irritating excipients such as cocoa butter, polyethylene glycol or any suppository wax which is a solid at room temperature, but liquid at body io temperature and therefore melt in the rectum or vaginal cavity to release the active component(s). The compounds are dissolved in the melted wax, formed into the desired shape, and allowed to harden into the finished suppository formulation.
Compounds of the present invention may also be administered in the form of liposomes. As is know in the art, liposomes are generally derived from phospholipids or other lipid substances. Lipososome formulations are formed by mono- or multilamellar hydrated liquid crystals which are 2o dispersed in an aqueous medium. Any non-toxic, pharmaceutically acceptable, and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to one or more active compounds of the present invention, stabilizers, excipients, preservatives, and the like. The preferred lipids are phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic.
Methods for forming liposomes are know in the art as described, for example, in Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N. Y. (1976), p. 33 et seq.
Dosage forms for topical administration of the compounds of the present invention include powders, sprays, ointments, creams, and inhalants. The active ingredients) is mixed under sterile conditions with a suitable pharmaceutically acceptable carrier and preservatives, buffers, or propellants as needed. Opthalmic formulations, eye ointments, and solutions are also contemplated as falling within the scope of the present invention.
Actual dosage levels of compounds of the present invention are varied so as to administer an amount of the compound which is effective to bring about the desired therapeutic affect. The dose required for a given patient io will vary depending upon the severity of the condition being treated, the age, weight, and sex of the patient, as well as the state of health of the patient. However, it is within the skill of the art to "dose titrate" the patient; that is, to begin administering a dose known to be below the amount ~5 required to bring about the desired therapeutic effect and to gradually increase the dose until the desired effect is achieved.
Generally, for the treatment of estrogen-related disorders, compounds of the present invention are 2o administered at dosage levels between about 10 mg/kg of body weight and about 250 mg/kg of body weight per day. If desired, the daily dosage may be divided into multiple doses for purposes of administration, e.g. into two to four doses per day.
25 The following Examples are provided in order to enable one skilled in the art to practice the present invention.
However, the Examples are merely illustrative of the invention and are not to be read as limiting its scope which is defined by the appended claims.
Preparation 1 Preparation of acid chloride form of carboxypolystyrene resin To a suspension of carboxypolystyrene resin (20.0 g, Novabiochem, La Jolla, California, 92039) in benzene (200 mL) under nitrogen atmosphere was added dropwise and excess (20.0 mL) of oxalyl chloride. The resulting mixture was heated to 70°C for 20 hours, then cooled to ambient temperature. Additional benzene (100 mL) was added to the mixture which was stirred for 5 minutes, and the resulting resin allowed to settle. The supernate was removed via cannula. This procedure was repeated 5 times using 200 ml 1o benzene. After the final rinse, the resulting resin was dried under reduced pressure at 30°C until a constant mass (19.8 g) was obtained. Chlorine analysis showed the resin contained 8.09 C1 which corresponded to a new loading ratio of 2.29 mmol/g.
Preparatioa 2 Preparation of a Mixture of the Resin-Bound Phenolic Substrates HO HO
OMOM Resin O
and O
Resin O Ip MOMO
Zti!
Step 1 - Preparation of 6-methoxy-2-(4-methoxypheny_1)-1-(4-triisopropylsilyloxybenzoyl)-3,4-dihydro-naphthalene TI PSO
To a solution of 5.9 g (15.28 mmol) of 6-methoxy-2-(4-methoxyphenyl)-1-(4-hydroxybenzoyl)-3,4-dihydronaphthalene (prepared as described in Jones, et al., J. Med. Chem., 35:
*rB
931-938 (1992) in 200 mL of dichloromethane under a nitrogen atmosphere was added 1.87 g (15.28 mmol) of dimethylamino-pyridine and 4.1 mL (15.28 mmol) of triisopropyl trifluoromethane-sulfonate ("TIPS triflate," Aldrich Chemical Co., Milwaukee, WI). The resulting mixture was stirred at room temperature for 48 hours, after which time the reaction was quenched by addition of aqueous sodium bicarbonate solution. The resulting mixture was extracted twice with dichloromethane. The organic layers were combined, extracted with brine solution, dried over anhydrous sodium sulfate and concentrated under vacuum to yield 8.05 g (97~) of the title compound as a thick yellow oil.
1H NMR (300 MHz, CDC13). b Values: 1.06 (s, 9H), 1.19 (m, 1H), 2.79 2H), 3.01 (t, J 7.7, 7.8, 2H),3.69 (s, 3H), (m, =
3.79 (s, 3H),6.61-6.79 (m, 6H), 6.96 (d, J 8.49, 1H), =
7.17 (d, J 6.8, 2H), and 7.73 (d, = 7.13, 2H).
= J
Step 2 - Preparation of 6-hydroxy-2-(4-hydroxyphenyl)-1-(4-triisopropylsilyloxybenzyl)naphthalene TIPSO
OH
HO
To a solution of 8.05 g (14.85 mmol) of the product of step 1 in 200 mL of dichloromethane under a nitrogen atmosphere was added 5.8 mL (78.85 mmol) of ethanethiol followed by 8.41 g (63.08 mmol) of anhydrous aluminum chloride. The resulting mixture was stirred at room temperature for one hour and then cooled to 0°C. The cooled reaction mixture was quickly quenched by the addition of 3o saturated aqueous sodium bicarbonate. Water was added and the mixture was extracted three times with ethyl acetate.
The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, and concentrated under vacuum to yield 7.2 g of 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(triisopropylsilyloxy)benzoyl]naphthalene as a yellow solid.
This material was dissolved in 400 mL of tetrahydro-furan under a nitrogen atmosphere and the resulting mixture was cooled to 0°C. Lithium aluminum hydride (42 mL of a 1.0 M solution (42.0 mmol) was added dropwise to the cooled solution with vigorous stirring. This reaction mixture was stirred for 1.5 hours after which time the reaction was quenched by the addition of saturated aqueous sodium bicarbonate. The resulting mixture was extracted three time with ethyl acetate and the organic layers were combine, extracted with brine, dried over anhydrous sodium sulfate, t5 and conentrated under vacuum. The solid residue was taken up in 300 mL of ethyl acetate and a catalytic amount of gaseous hydrogen chloride was bubbled through the solution.
The solution was stirred at room temperature for 30 minutes and then quenched with saturated aqueous sodium bicarbonate solution.
This mixture was extracted three times with ethyl acetate, and the organic layers were combines, extrcated with brine, dried over sodium sulfate, and concentrated under vacuum to yield 2.8 g (5.61 mmol, 38~) of the title compound as a yellow foam.
1H NMR (300 MHz, CDC13). 8 Values: 1.06 (s, 9H), 1.19 (m, 1H), 4.31 (s, 2H), 4.71 (s, 1H), 4.99 (s, 1H), 6.72 - 6.85 (m, 6H), 7.02 (dd, J = 6.6, 2.5, 1H), 7.14 (d, J = 8.4, 2H), 7.19 (d, J = 2.5, 2H), 7.40 (d, J = 8.8, 1H), 7.65 (d, ?J =
8.5, 1H), and 7.83 (d, J = 9.1, 1H).
Step 3 - Preparation of mixture of 6-hydroxy-2-(4-metho methoxyphenyl)-1-(4-triisopropylsilyloxybenzoy_1_)-naphthalene and 6-methoxymethoxy-2-(4-hydroxy-phenyl)-1-(4-triisopropylsilyloxybenzoyl)-naphthalene TIPSO TIPSO
OMOM OH
HO~ MOMO
The product of step 2 (2.8 g, 5.61 mmol) was dissolved in 200 mL of acetonitrile under nitrogen at room 1o temperature. To this mixture were 0.78 g (5.61 mmol) of potassium carbonate and a catalytic amount (20 mg) of 1,4,7,10,13,16-hexaoxacyclooctadecane ("18-crown-6" ether, Aldrich Chemical Co., Milwaukee, WI, USA) and 0.43 mL (5.61 mmol) of methoxymethyl chloride (Aldrich Chemical Co., Milwaukee, WI, USA). This mixture was stirred at room temperature for 24 hours after which time the reaction was quenched by the addition of saturated sodium bicarbonate.
The reaction mixture was extracted three times with ethyl acetate and the organic layers combined and extracted 2o with brine solution. The organic solution was dried over anhydrous sodium sulfate and concentrated under vacuum.
Flash chromatograohy of the resulting oil on silica, eluting with dichloromethane yielded 1.37 g (45~) of a mixture of the two products as a yellow foam.
Step 4 - Preparation of mixture of resin-bound 6-hvdroxv-2 (4-methoxymethoxyphenyl)-1-(4-triisopropyl-silyloxybenzoyl)naphthalene and 6-methoxymethoxy-2-(4-hydroxyphenyl)-1-(4-triisopropylsilyloxy-benzoyl)naphthalene TIPSO TIPSO
Resin OMOM ' O
O O
O MOMO~
Resin To a solution in 25 mL of dichloromethane of 1.88 g (3.46 mmol) of the product mixture from step 3 were added, under nitrogen, 0.97 mL (6.92 mmol) of triethylamine and 1.51 g (3.46 mmol) of the resin in its acid chloride form (prepared as described in Preparation 1 above). The mixture was stirred gently at room temperature for 19 hours. After this time the reaction was quenched by the addition of 2 mL
of methanol and the resulting mixture was stirred at room temperature for an additional 5 minutes. The reaction mixture was filtered and the filter residue was washed successively with 150 mL portions of dichloromethane, methanol, and dichloromethane to yield 2.95 g of the loaded 2o resin with a loading ratio of 1.17 mmol/g.
Step 5 - Preparation of the mixture of resin-bound 6-hydroxy-2-(4-methoxymethoxyphenyl)-1-(4-hydroxybenzyl)naphthalene and 6-metho_x_y-methoxy-2-(4-hydroxyphenyl)-1-(4-hydroxybenzyl)-naphthalene HO HO
OMOM Resin O
O and O
Resin O ~ MOMO
Z~
preparation 3 Preparation of the Betaine Coupling Catalyst O;g~O PPh3 After the method of J. Castro, et al., J. Org. Chem., 59:2289-2291 (1994), to a stirred mixture of triphenyl-phosphine (8.73 g, 33.28 mmol) and 5.0 g (33.28 mmol) of 3,3-dimethyl-1,2,5-thiazolidine 1.1-dioxide in 100 mL of tetrahydrofuran under nitrogen were added, dropwise over a period of ten minutes, 5.25 mL (33.28 mmol) of diethylazo-dicarboxylate (DEAD). The resulting mixture was stirred at room temperature for 3 hours and the white solid precipitate which formed was collected by filtration and washed successively once with 20 mL of tetrahydrofuran and twice with 20 mL portions of diethyl ether. The material was dried under high vacuum over phosphorus pentoxide to yield 13.2 g (96~) of the title betaine, m.p. 169-172°C.
General Method for the Preparation of the Compounds of 8xamples 1-16 Z.Y,X.O Z.Y,X.O
OMOM Resin O
O aad O
Resin O ~ MOMO- v "
$2 Step 1 Coupling of the resin-bound and substrate alcohols Reactions were run in a 96-well plate which had been drilled and fitted with filter frits. A mixture of the substrate alcohol (0.4 mL of a 1 molar solution in toluene, 0.04 mmol), 30 mg of the loaded resin beads (0.04 mmol), and 0.4 mmol (0.4 mL of a 1 molar suspension in dichloromethane) were placed in each of well.
The plate was sealed and rotated for 168 hours at room temperature. At the end of this time, each well was filtered through its frit and the residue was washed successively with portions of tetrahydrofuran, dichloro-methane, dimethylformamide, methylene chloride, and tetrahydrofuran.
1o _Step 2 Cleavage of the derivatized, methoxymethyl-protected intermediates from the resin To each cell was added 0.8 mL of a 20~ solution of n-propylamine in tetrahydrofuran. The plated was sealed and vortexed for 24 hours. The contents of each cell were filtered into a normal 96-well plate, collecting each of the cleaved, methoxymethyl-protected intermediates in its own well on the new plate. Each transferred was followed by a rinse of the reaction cells with 15~ dichloromethane in methanol.
Step 3-- Removal of the methoxymethyl protecting grou To each cell of the new plate containing the cleaved intermediates described in step 2 was added 3.2 mmol of HC1 (4 molar in dioxane). The plate was sealed and vortexed overnight. At the end of this time, the solvent and excess HC1 were removed under vacuum to yield, in each well of the plate, the end-product of each Example below.
While standard methods of combinatorial chemistry were employed in preparing small amounts of each compound 3o exemplified below, it is within the skill of a practitioner of the organic chemical art to employ the reactions and reagents taught to prepare larger amounts of the compounds if needed.
WO 99/07377 PCT/iJS98/16065 Exaa~les 1-16 Each of the Examples below were prepared by the method detailed above. In each case, the molecular weight of the title compound was determined by the ion spray mass spectrometric method and the biological activity determined by the assay described below.
Example 1 OH
"., 6-Hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-methylpyrrolidin-2-yl)methoxy-benzyljnaphthalene hydrochloride C29H29N03~HCl Mass: (Calc.): 439 (-HC1) (Found): 440 Inhibition of MCF7 cell proliferation: ED50 = 0.5 nM
2o Exaa4ple a 6-Hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N,N-diethylamino) propoxy)benzyl]naphthalene hydrochloride C28H29N03~HC1 Mass: (Calc.): 455 (-HC1) (Found): 456 Inhibition of MCF7 cell proliferation: ED50 = 0.9 nM
Bxample 3 CH3 ~ HCI
H9C "N
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(N,N-diisopropyl-amino)ethoxy)benzyl]naphthalene hydrochloride C31H35N03~HC1 Mass: (Calc.): 469 (-HC1) (Found): 469 Inhibition of MCF7 cell proliferation: ED50 = 2 nM
8xample 4 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-methylpiperidin-2-yl) methoxybenzyl]naphthalene hydrochloride ..
N
i ~ HCI
C29H29N03~HCl Mass: (Calc.): 453 (-HC1) (Found): 454 Inhibition of MCF7 cell proliferation: ED50 = 2 nM
Example 5 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-methylpiperidin-3-yl) methoxybenzyl]naphthalene hydrochloride .N(~0 HCI OH
/~
HO ~
C30H31N03~HCl Mass: (Calc.): 453 (-HC1) (Found): 454 Inhibition of MCF7 cell proliferation: ED50 = 2 nM
~o 8xamyle 6 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(N,N-di-n-butylamino) ethoxy)benzyl]naphthalene hydrochloride H3C~N~0 /
~ J HCI ~ OH
H3C' v /
/
HO
C33H39N03~HC1 Mass: (Calc.): 497 (-HC1) (Found): 498 Inhibition of MCF7 cell proliferation: ED50 = 2 nM
$xampl~ 7 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N,N-di-n-butylamino) propoxy)benzyl]naphthalene hydrochloride C34H41N~3'HC1 Mass: (Calc.): 511 (-HC1) (Found): 512 Inhibition of MCF7 cell proliferation: EDS~ = 4 nM
io 8xam~le 8 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-(4-acetylphenyl)piperazin-1-yl)ethoxy)benzyl]-naphthalene dihydrochloride N~
OH
H3C ~ ~ 2 HCI
O
C37H36N2~4'2 HCl Mass: (Calc.): 572 (- 2 HC1) (Found): 573 2o Inhibition of MCF7 cell proliferation: EDS~ = 4 nM
Example 9 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(naphth-1-ylamino)propoxy)benzyl]naphthalene hydrochloride H
NCO
~ HCI E O
O
C36H31N03'HC1 Mass: (Calc.): 525 (-HC1) (Found): 526 Inhibition of MCF7 cell proliferation: ED50 - 9 nM
Exaa4ple 10 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N,N-di-n-butylamino) hexoxy)benzyl]naphthalene hydrochloride ~ HCI
C3~H4~N03~HC1 Mass: (Calc.): 525 (Found): 526 Inhibition of MCF7 cell proliferation: ED50 = 10 nM
Exan~yle 11 N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl methyl)phenoxy)ethyl]-N'-5-chloro-2 methylphenyl urea CI
N~N~/O /
H3 H ~CH ~ ~ / OH
/ /
HO
Mass: (Calc.): 580 (Found):
1o Inhibition of MCF7 cell proliferation: ED50 = 10 nM
Example 12 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(2,3,5,6 tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl)ethoxy)benzyl)naphthalene CH3 H ~ HCI
O~N N~ ~
H C~N T 'N
O
C32H30N4~5 Mass: (Calc.): 550 (Found): 548 Inhibition of MCF7 cell proliferation: ED50 = 20 nM
8xample 13 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(2,6 dimethylmorpholin-4-yl)ethoxy)benzyl]naphthalene hydrochloride HCI
H3C~N~0 O J ~ I / OH
HO
C31H33N~4'HC1 Mass: (Calc.): 483 (-HCl) (Found): 483 Inhibition of MCF7 cell proliferation: ED50 = 20 nM
8xaa~ple 14 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(azaspiro[5.5]undec-4 yl)propoxy)benzyl]naphthalene hydrochloride NCO
HCI ~ ( OH
HO
C36H41N~3'HC1 Mass: (Calc.): 535 (-HC1) (Found): 536 Inhibition of MCF7 cell proliferation: ED50 = 30 nM
8xam~le 15 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(pyrollidinon-1 yl)ethoxy)benzyl]naphthalene NCO
I ~ off I
Ho ~
C29H27N~4 Mass: (Calc.): 453 (Found): 454 Inhibition of MCF7 cell proliferation: ED50 = 40 nM
8xaa~ple 16 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(pyrollidinon-2 yl)propoxy)benzyl]naphthalene I
O OH
nv C30H29N~4 Mass: (Calc.): 467 (Found): 468 Inhibition of MCF7 cell proliferation: ED50 = 30 nM
Biological Activity of the Compounds of the Present Invention - MCF-7 Proliferation Assay The data reported in each of the Examples given above for inhibition of MCF-7 cell proliferation were obtained in an assay which determined each compound's ability to inhibit the proliferation of MCF-7 breast adenocarcinoma cells.
In the assay, these cells (ATCC HTB 22) are maintained in minimal essential medium, phenol red-free, (Sigma, St.
Louis, MO) supplemented with 10~ (V/V) fetal bovine serum (FBS), L-glutamine (2 mM), sodium pyruvate (1 mM), HEPES
~(N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid] 10 mM}, non-essential amino acids and bovine insulin (1 ug/mL) (maintenance medium). Ten days prior to assay, MCF-7 cells 1o are switched to maintenance medium supplemented with 10~
dextran coated charcoal stripped fetal bovine serum (DCC-FBS) assay medium) in place of 10~ FBS to deplete internal stores of steroids. MCF-7 cells are removed from maintenance flasks using cell dissociation medium (Ca++/Mg++
free HBSS (phenol red-free) supplemented with 10 mM HEPES
and 2 mM EDTA). Cells are washed twice with assay medium and adjusted to 80,000 cells/mL. Approximately 100 mL
(8,000 cells) are added to flat-bottom microculture wells (Costar 3596) and incubated at 37° C in a 5~ C02 humidified 2o incubator for 48 hours to allow for cell adherence and equilibration after transfer. Serial dilutions of drugs or DMSO as a diluent control are prepared in assay medium and 50 mL transferred to triplicate microcultures followed by 50 mL assay medium for a final volume of 200 mL. After an additional 48 hours at 37° C in a 5~ C02 humidified incubator, microcultures are pulsed with tritiated thymidine (1 uCi/well) for 4 hours. Cultures are terminated by freezing at -70° C for 24 hours followed by thawing and harvesting of microcultures using a Skatron Semiautomatic Cell Harvester. Samples are counted by liquid scintillation using a Wallac BetaPlace ~ counter. Activity of a compound of formula I in this present assay demonstrates that the compound is of potential value for treating hormonally-dependent cancer, particularly breast cancer.
More particularly, the present invention concerns a class of 1-[4-(substituted alkoxy)benzyl]naphthalene io compounds having estrogenic activity, to pharmaceutical compositions containing the compounds and to a method of treating or inhibiting cancer of the breast or uterus.
Background of the Invention Estrogen is a generic term for estrus-producing steroid compounds. Within the "estrogen group" are the traditional steroids such as 173-estradiol and estrone (the major estrogens in humans), as well as various metabolites such as the estratriols, sulfates and glucuronides of estradiol and 2o estrone. Also, germane to human medicine, are the steroidal equine estrogens such as the equilins, in that they are administered to humans in preparations, such as Premarin=".
Also, certain compounds known as "anti-estrogens", e.g., tamoxifen, clomiphene, and nafoxidene, demonstrate varying degrees of estrogen agonist properties in some tissues;
however they act to antagonize the natural estrogens and their function in other tissues.
Recently, these uanti-estrogens" have been categorized into three different types depending on their degree and mix of estrogen agonist/antagonist properties which is based on their ability to freeze estrogen receptors in different conformational states, cf. D. P. McDonnell, et al., Molecular Endocrinology, 9(6): 659-669 (1995). Most germane are the type II anti-estrogens of which compounds of the current invention belong.
Estrogens as biologically active molecules exert their properties by binding to an intracellular receptor. After the receptor and bound ligand are transported to the nucleus of a cell, the complex exerts its effect by binding to certain recognition sites on DNA and allowing certain genes to be expressed. This binding to the receptor and regulation is not completely understood at this time;
1o however, it appears to be crucial to the varying degree of agonistic and antagonistic properties of a molecule. Thus, certain types of so-called "anti-estrogens" allow agonist activity in some tissues, but are antagonists in others.
Hence, the term, "selective estrogen receptor modulators ~5 (SERMs)" has been proposed to describe these molecules, especially the type II, of which the compounds of the present invention are members.
Estrogen has long been classified as "the female sex hormone" and a voluminous literature describes its activity 2o as such. However, in recent years, research has shown that estrogens have many other homeostatic functions, other than those related to female reproduction and function of sex tissues. Indeed, it has been shown that males possess estrogen receptors and DNA recognition sites and possess the 25 ability to produce estrogens and many tissues, such as those involved in the cardiovascular system. The exact nature of the effects of estrogens in both men and women, outside the productive aspects, are only beginning to be explored and are currently poorly understood.
3o The majority of the documented activities of the estrogens have been derived from studies in women, since most women suffer from the most obvious effects of estrogen, mainly due to menopause and estrogen dependent cancers. The clinical pathologies associated with estrogen levels and 35 their subsequent function, can be categorized into two main types, i.e., those which are due to a deprivation or lack of _3-estrogen and those which are due to an aberrant physiological response to existing estrogen in estrogen sensitive tissues. SERMS, especially those of type II, have the property of being estrogen agonists in those cases where estrogen deprivation is a cause of pathology (mainly in non-sex related tissues) and simultaneously being antagonists of the pathologies caused by abnormal responses to endogenous estrogen (in sex related tissues).
Thus, SERMS of the type II have the potential to to effectively treat a variety of estrogen dependent pathological conditions. This dual effect is an intrinsic and unique property of the molecules of the present invention.
Summary of the Invention In its principal embodiment, the present invention provides a selective estrogen modulating compound of structure 1:
,Y
Z
or a pharmaceutically acceptable salt thereof where R1 and R2 are independently selected from hydrogen, alkyl of one to six carbon atoms, acyl of two to six carbon atoms, and phenacyl.
The group designated X is -(CH2)n where n is an integer of one to 6, inclusive.
Y is absent or is selected from the group consisting of 1,4-piperazinylene; ureido; N-(lower alkyl)ureido; N'-(lower alkyl)ureido; and N, N'-(di-lower alkyl ureido.
3o The substitutent Z is selected from the group consisting of 1-, 2- or 3-pyrrolidinyl; 1-, 2-, or 3-[1-(lower alkyl)pyrrolidinyl]; 1- 2-,3- or 4-piperidinyl; 1-, 2-, 3- or 4-[1-lower alkyl)piperidinyl]; N,N-dialkyl in which the alkyl groups are independently from one to four carbon atoms; 1-azepinyl; 1- or 2-naphthylamino;
morpholinyl; dimethyl-4-morpholinyl; 3-azaspiro[5.5]undecan-3-yl; pyrrolidinon-1-yl; unsubstituted phenyl; and phenyl substituted with one or two groups independently selected from acyl of two to four carbon atoms, alkyl of one to four carbon atoms, halo, and alkoxy of one to four carbon atoms.
io All of the above definitions are with the proviso that n is not 2 or 3 when Z is 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, N,N-dimethylamino or N,N-diethyl-amino.
In a second embodiment, the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound as defined above in combination with a pharmaceutically acceptable carrier.
In another embodiment, the present invention comprises a method of treating or inhibiting estrogen-dependent 2o cancers in women, particularly cancer of the breast and uterus, comprising administering to a woman in need of such treatment an effective amount of a compound as defined above.
Detailed Description As used throughout this specification and the appended claims, the following terms have the meanings ascribed to them.
"Alkyl of one to six carbon atoms" means a univalent 3o radical derived by the removal~of one hydrogen atom from methane, ethane, or a straight or branched hydrocarbon of three to six carbon atoms and is typified by methyl, ethyl, n- or iso-propyl, n-, sec- iso- or tent-butyl, n-pentyl, 2-methylbutyl, n-hexyl, 2-methylpentyl, 2,3-dimethylbutyl, and the like.
"Acyl" denotes an alkyl group as defined above, attached to the parent molecular moiety through a carbonyl group.
"Lower alkyl" denotes an alkyl group as defined above containing one to four carbon atoms.
The term "alkoxy" refers to an alkyl group, as defined above, attached to the parent molecular moiety through an 1o oxygen atom.
The term "1,4-piperazinylene" denotes a divalent radical of the structure:
n -N N
U.
and the term "ureido" means the divalent radical represented by the structure H H
~N~N~
O
The term "N-(lower alkyl)ureido", as used herein, means a ureido group in which the lower alkyl group is attached to the nitrogen nearest the group denoted "X" in structure 1 above, thus:
H alkyl Z.N~N.X~
fIO
and "N'-(lower alkyl)ureido" means a ureido group in which the lower alkyl group is attached to the nitrogen nearest the group denoted "Z" in structure I above, thus:
*rB
~Ikyl H
Z.N~N.X~
IIO
Compounds contemplated as falling within the scope of the present invention include, but are not limited to, the following representative examples.
Compounds of the present invention in which Y is absent, and Z is alkyl or dialkyl include:
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-methylamino)methoxy-benzyl]naphthalene;
io 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N,N-dimethylamino)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-isopropylamino)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N,N-diisopropylamino)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(N-isopropylamino)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N-isopropylamino)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N,N-diisopropyl-amino)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N-butylamino)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N,N-dibutylamino)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N-methylamino)-hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N,N-dimethylamino)-3o hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N-ethylamino)-hexoxy)benzyl]naphthalene;
WO 99!07377 PCT/US98/16065 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(5-(N,N-diethylamino)-hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N-isopropylamino)-hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N,N-diisopropyl-amino)hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N-butylylamino)-hexoxy)benzyl]naphthalene; and 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N,N-dibutylamino)-1o hexoxy)benzyl]naphthalene.
Examples of compounds of the present invention in which X is alkylene, Y is absent, and Z is pyrrolidinyl include:
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(pyrrolidin-1-yl)methoxy-benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(pyrrolidin-2-yl)methoxy-benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(pyrrolidin-3-yl)methoxy-benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(pyrrolidin-2-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(pyrrolidin-3-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(3-(pyrrolidin-2-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(pyrrolidin-3-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(4-(pyrrolidin-1-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(pyrrolidin-2-yl)-butoxy)benzyl]naphthalene; and 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(pyrrolidin-3-yl)-butoxy)benzyl]naphthalene.
_g_ Compounds of the present invention in which Y is absent, and Z is pyrrolidinon-1-yl include:
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(pyrrolidinon-1-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(pyrrolidinon-1-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(pyrrolidinon-1-yl)-1o propoxy)benzyl]naphthalene; and 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(pyrrolidinon-1-yl)-butoxy)benzyl]naphthalene.
Compounds of the present invention in which Y is absent, and Z is piperidinyl include:
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(piperidin-1-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(piperidin-2-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-methylpiperidin-2-yl)-2o methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(piperidin-3-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-methylpiperidin-3-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(piperidin-4-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(piperidin-2-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(piperidin-3-yl)-3o ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(piperidin-4-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(piperidin-2-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(piperidin-3-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(piperidin-4-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(4-(piperidin-1-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(piperidin-2-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(piperidin-3-yl)-to butoxy)benzyl]naphthalene; and 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(piperidin-4-yl)-butoxy)benzyl]naphthalene.
Compounds of the present invention in which Y is absent and Z is azepinyl include:
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(azepin-1-yl)methoxy-benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(azepin-2-yl)methoxy-2o benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(azepin-3-yl)methoxy-benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(azepin-4-yl)methoxy-benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(azepin-2-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(2-(azepin-3-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(azepin-2-yl)-3o propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(azepin-3-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(azepin-1-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(azepin-2-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(azepin-3-yl)-butoxy)benzyl]naphthalene; and 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(azepin-4-yl)-butoxy)benzyl]naphthalene.
Compounds of the present invention in which Y is absent and Z is 4-morpholinyl include:
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(morpholin-4-yl-methoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[(4-(4-(morpholin-4-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(5-(morpholin-4-yl)-heptoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(morpholin-4-yl) hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2,6-dimethylmorpholin-4-2o ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(2,6-dimethyl-morpholin-4-yl)ethoxy)benzyl]naphthalene; and 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(2,6-dimethyl-morpholin-4-yl)propoxy)benzyl]naphthalene.
Compounds of the present invention in which Y is absent and Z is 1- or 2-aminonaphthyl include:
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(naphth-1-ylamino) 3o methoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(naphth-1-ylamino)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(naphth-1-ylamino)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(naphth-1-ylamino)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(naphth-2-ylamino)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(naphth-2-ylamino)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(naphth-2-ylamino)-propoxy)benzyl]naphthalene; and 5-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(naphth-2-ylamino)-io butoxy)benzyl]naphthalene.
Compounds of the present invention in which Y is absent and Z is 3-azaspiro[5.5]undec-3-yl include:
t5 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-azaspiro[5.5]undec-3-yl)methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(3-azaspiro[5.5]undec-3-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(3-azaspiro[5.5]undec-20 3-yl)propoxy)benzyl]naphthalene; and 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(3-azaspiro[5.5]undec-3-yl)butoxy)benzyl]naphthalene.
Compounds of the present invention in which Y is absent 25 and Z is 2,3,5,6-tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl include:
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2,3,5,6-tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl)methoxybenzyl]-naphthalene;
30 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(2,3,5,6-tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl)ethoxy)benzyl]-naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(2,3,5,6-tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl)propoxy)benzyl]-naphthalene; and 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(2,3,5,6-tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl)butoxy)benzyl]-naphthalene.
Compounds of the present invention in which Y is 1,4-piperazinylene and Z is phenyl or substituted phenyl 1o include:
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-phenylpiperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-phenylpiperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-phenylpiperazin-1-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-phenylpiperazin-1-yl)butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-methylphenyl) piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-chlorophenyl)-piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-hydroxyphenyl)-piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-methoxyphenyl)-piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(4-(4-acetylphenyl)-piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(2-(4-(4-methylphenyl)-piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-(4-chlorophenyl)-piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-(4-hydroxyphenyl)-piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-(4-methoxyphenyl)-piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(2-(4-(4-acetylphenyl)-piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-methylphenyl)-piperazin-1-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-chlorophenyl)-piperazin-1-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-hydroxyphenyl)-piperazin-1-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-methoxyphenyl)-piperazin-1-yl)propoxy)benzyl]naphthalene; and t5 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-acetylphenyl)-piperazin-1-yl)propoxy)benzyl]naphthalene.
Compounds of the present invention in which Y is ureido and Z is phenyl or substituted phenyl include:
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-phenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenyl)ethyl]-N'-phenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-phenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-4-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-4-chlorophenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-4-hydroxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-4-methoxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-3-chloro-2-methylphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl) phenyl)ethyl]-N'-4-methylphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenyl)ethyl]-N'-4-chlorophenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenyl)ethyl]-N'-4-hydroxyphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenyl)ethyl]-N'-4-methoxyphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl) phenyl)ethyl]-N'-3-chloro-2-methylphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-4-methylphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-phenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-4-chlorophenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-4-hydroxyphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-4-methoxyphenyl urea; and N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-3-chloro-2-methylphenyl urea.
Compounds of the present invention where Z is N-alkylureido and Z is phenyl or substituted phenyl include:
3o N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1 ylmethyl)phenylmethyl]-N'-phenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-phenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-2-ylmethyl)phenylpropyl]-N'-phenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-methylphenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-chlorophenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-hydroxyphenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-1o ylmethyl)phenylmethyl]-N'-4-methoxyphenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-3-chloro-2-methylphenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-methylphenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-chlorophenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-hydroxyphenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1 2o ylmethyl)phenyl)ethyl]-N'-4-methoxyphenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-3-chloro-2-methylphenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-methyiphenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-phenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-chlorophenyl urea;
3o N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-hydroxyphenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-methoxyphenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-3-chloro-2-methylphenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-methylphenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-chlorophenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyi)phenylmethyl]-N'-4-hydroxyphenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-1o ylmethyl)phenylmethyl]-N'-4-methoxyphenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-3-chloro-2-methylphenyl urea;
N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-methylphenyl urea;
t5 N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-chlorophenyl urea;
N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-hydroxyphenyl urea;
N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-2o ylmethyl)phenyl)ethyl]-N'-4-methoxyphenyl urea;
N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-3-chloro-2-methylphenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-methylphenyl urea;
25 N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-phenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1 ylmethyl)phenylpropyl]-N'-4-chlorophenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-3o ylmethyl)phenylpropyl]-N'-4-hydroxyphenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-methoxyphenyl urea; and N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyi)phenylpropyl]-N'-3-chloro-2-methylphenyl urea.
Examples of compounds of the present invention where Y
is N'-alkylureido and Z is phenyl or substituted phenyl include:
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-phenyl urea;
N-[4-(2-(&-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenyl)ethyl]-N'-methyl-N'-phenyl urea;
1o N-(4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-ethyl-N'-phenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-4-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-4-chlorophenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-4-hydroxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-4-methoxyphenyl urea;
2o N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-3-chloro-2-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-ethyl-N'-4-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-ethyl-N'-4-chlorophenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-ethyl-N'-4-hydroxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-3o phenylmethyl]-N'-ethyl-N'-4-methoxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-ethyl-N'-3-chloro-2-methylphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenyl)ethyl]-N'-methyl-N'-4-methylphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl) phenyl)ethyl]-N'-methyl-N'-4-chlorophenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl) phenyl)ethyl]-N'-methyl-N'-4-hydroxyphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenyl)ethyl]-N'-methyl-N'-4-methoxyphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenyl)ethyl]-N'-methyl-N'-3-chloro-2-methylphenyl urea;
1o N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-ethyl-N'-4-methylphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl) phenylpropyl]-N'-ethyl-N'-phenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-~5 phenylpropyl]-N'-ethyl-N'-4-chlorophenyl urea;
N-(4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'ethyl-N'-4-hydroxyphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-ethyl-N-4-methoxyphenyl urea; and 20 N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylpropyl]-N'-ethyl-N'-3-chloro-2-methylphenyl urea.
The compounds of the present invention are synthesized by standard methods known to practitioners of the organic 25 chemical arts using starting materials which are either commercially available or are prepared by methods disclosed in the chemical literature.
In the present invention, the compounds were prepared by methods of parallel combinatorial synthesis using the 3o process depicted in Reaction Scheme 1. Thus, in each Example presented below, only small amounts of each compound were prepared for purposes of pharmacological evaluation.
It will be understood by chemists skilled in the organic chemical art that, if required, larger quantities of each compound disclosed within this specification can be made using the reactions and reagents taught for the combinatorial processes disclosed.
Referring to Reaction Scheme 1, the starting material for the process, [3,4-dihydro-6-methoxy-2-(4-methoxyphenyl)-1-naphthalenyl](4-hydroxyphenyl)methanone, 2, is prepared according to the method disclosed by Jones, et al., J. Med.
Chem., 35: 931-938 (1992). The free alcohol function of compound 2 is converted to the triisopropylsiloxyl residue of compound 3 by reaction of 2 with triisopropylsiloxyl triflate (Aldrich Chemical Co., Milwaukee, WI, USA). The reaction is generally carried out by the method of E. J.
Corey, et al., Tetrahedron Lett., 22: 3455 (1981) in dichloromethane in the presence of an acid scavenger such as diisopropylethylamine. The methoxy groups of compound 3 are next removed by reaction of 3 with aluminum chloride and ethanethiol using the method of Node, et al, Chem. Lett., 97 (1979). Subsequent reaction of 3 with lithium aluminum hydride reduces the linking carbonyl group and concomitantly 2o aromatizes the tetrahydronaphthyl ring system of 3 to the naphthyl ring system of 4 after acid treatment.
Compound 4 is next reacted with methoxymethyl chloride (MOM-C1) using the methods disclosed by G. Stork, et al., J.
Am. Chem. Soc., 99: 1275 (1977). This process produces a mixture of isomers 5a and 5b which are carried forward without separation.
Reactioa Scheme 1 HO TIPSO
TI PSOTf 1. AICi3 / EtSH
2. LAH
3. HCI
TIPSO
OH
MOMCI HO ~ MOMCI
TlPSO TIPSO
OMOM OH
HO MOMO~
CI
Resin CI Resin O O
TIPSO
Resin O
O
MOMO_ v v TBAF TBAF
HO HO
OMOM Resin O
O
O~
Resin ~ MOMO
l~
The mixture of isomers, 5a and 5b are next reacted with the acid chloride form of the resin to attach the both triisopropylsilyl protected isomers to the resin backbone.
Reaction Scheme 1 (continued) HO
HO
OMOM Resin O
O ~ O
Resin O 1~ MOMO
.X. .Z .X. .Z
HO Y HO Y I~ ~l~p ph )3 't~ N.p~ph)a O~S~O
S
O % ~ p Z.Y,X.O
Z.Y.X.O O
OMOM Resin O
O MOMO
Resin O $~ $
n-PrNH2 n-PrNH2 Z.Y.X.O Z.Y.X.O
OMOM OH
HO ~ MOMO
1;3!
Z.Y.X.O
OR' R' O'~
1~
Z.Y.X.O
OH
HO~
This process is carried out in an aprotic organic solvent, such as dichloromethane, by reacting the acid chloride form of the resin with the protected alcohol mixture in the presence of an amine acid scavenger such as triethylamine.
The reaction is typically carried out by gently stirring the mixture (to avoid mechanical breakage of the resin beads) at room temperature for a period of from 8 to 24 hours. The loaded resin, 6a and 6b is then collected by filtration and washed free of the unreacted substrate.
1o Deprotection of the mixture, 6a and 6b with tetra-n-butylammonium fluoride in tetrahydrofuran, using the method of S. V. Frye, Tetrahedron Lett., 27: 3223 (1986) removes the triisopropylsilyl protecting group and yields the mixture of resin-bound, deprotected isomers 7a and 7b.
i5 The mixture of resin-bound intermediates, 7a and 7b, is next derivatized at the free hydroxyl position by reaction of the free phenolic functions of 7a and 7b with a commercially available alcohol, ZYX-OH, under Mitsunobu conditions (see J. L. Castro, et al., J. Org. Chem., 59:
20 2289-2291 (1994). These couplings were carried out by combinatorial chemistry means by placing 30 mg (0.04 mmol of the mixture of resin-bound phenolic substrates 7a and 7b in each well of a 96-well plate, together with 0.4 mL of a 1 molar solution of the particular alcohol in toluene. To 25 each well was also added 0.4 mL of a 1 molar suspension of a betaine coupling reagent having the structure N. .N-PPh 0 S..O s The derivatized, resin-bound mixture of intermediates 8a and 8b are then subjected to cleavage by reaction with 3o n-propylamine at room temperature for a period of about 24 hours to produce the methoxymethyl protected compound mixture 9a and 9b.
In the instances where the desired end-product is a 6-hydroxy-2-(4-hydroxyphenyl)naphthalene of structure la where both R1 and R2 are hydrogen, the methoxymethyl protecting groups of 9a and 9b are removed by reaction with acid, typically a trace of 4 molar hydrochloric acid in dioxane, according to the method of J. Auerbach, et al., J. Chem.
Soc., Chem. Commun., 298 (1974).
The compounds of structure 1b in which the groups designated R1 are both the same can be prepared directly from la by ether-forming or esterification reactions well known in the art.
Referring to Reaction Scheme 2, in the instance where t5 the desired end product of the reaction is a compound of structure le in which R1 is alkyl, alkylcarbonyl, or phenylcarbonyl, compound mixture 9a and 9b is first separated by conventional means such as column chromatography. Compound 9a is then reacted under basic 2o conditions to produce the desired methoxymethyl protected ether or ester, lc, followed by cleavage of the methoxymethyl protecting group to yield the desired product, 1e.
In a similar fashion, if the desired end-product is a 25 compound of structure if where R2 is is alkyl, alkylcarbonyl, or phenylcarbonyl, compound 9b (separated from its isomer) is reacted under basic conditions to produce the desired methoxymethyl protected ether or ester, 1e, followed by cleavage of the methoxymethyl protecting 30 group to yield the desired product, lf.
Specifically, when is it desired that R1 be alkyl, compound 9 is reacted with a suitable base such as potassium Reaction Scheaae 2 Z.Y.X.O Z.Y.X.O
' OMOM OH
HO ~ MOMO
Z.Y.X.O Z.Y.x.O
R'O MOMO~~~
1~ 1~
Z.Y.X.O Z.Y.X.O
OH OR
R'O'B HO
le Z.Y,X.O Z.Y,X.O
R'O R'O
15~
carbonate to yield the corresponding phenolate which is then reacted under typical Williamson ether synthesis conditions with an alkyl chloride to produce the alkyl ether, lb. In a similar manner, when it is desired that R1 be alkoxycarbonyl, the base-generated phenolate of 9 is reacted with the desired acid chloride in the presence of an acid scavenger such as triethylamine to produce lb. In those instances where R1 and R2 are the same in the desired end-product, the diethers or diesters are prepared by conventional means from compound la (cf. Reaction Scheme 1).
If, in the desired end-product, R1 and R2 are different and other than hydrogen, the free hydroxyl functions of intermediates la or 1f are converted by convention means to the desired ether, acyl, or phenacyl group.
Certain compounds falling within the scope of the present invention possess one or more chiral centers and are thus capable of existing in two or more enantiomeric or diastereomeric forms. The present invention contemplates all individual enantiomers of such compounds as well as mixtures thereof in cluding the racemic mixtures.
The individual enantiomers are obtained by methods well known in the art such as the separation by recrystallization of diastereomers formed by reacting racemic mixtures of the enantiomers with a resolved enantiomeric acid. The desired enantiomer is then regenerated from the diastereomeric salt by reaction with base. Alternatively, the individual enantiomers are separated from mixtures by means of standard 2o chromatigraphic separation techniques using "chiral columns," i.e. commercially available chromatographic columns charged with a chiral adsorbant.
The compounds~of the present invention in which the substituent Z contains a basic nitrogen atom are capable of forming acid addition salts with a wide variety of organic and inorganic acids and include the physiologically acceptable salts which are often used in the pharmaceutical formulation art. The present invention contemplates within its scope pharmaceutically acceptable acid addition salts of 3o compound of structure 1.
The term °pharmaceutically acceptable salts" denotes salts of the type described by S. M. Berge, et al., J.
Pharm. Sci., 66(1): 1-19 (1977) and includes typical inorganic acids such as hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, hypophosphoric and the like. Salts derived from organic acids, such as aliphatic mono and dicarboxylic acids, phenyl substituted alkanoic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, may also be used.
Such pharmaceutically acceptable salts include the acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, 1o hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, hydrobromide, isobutyrate, phenylbutyrate, i3-hydroxybutyrate, butyne-1,4-dioate, hexyne-1,4-dioate, caprate, caprylate, hydrochloride, cinnamate, citrate, formate, fumarate, glycollate, heptanoate, hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, teraphthalate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate, benzene-sulfonate, p-bromophenylsulfonate, chlorobenzenesulfonate, ethanesulfonate, 2-hydroxy-ethanesulfonate, methanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate, xylenesulfonate, tartarate, salts and the like.
A preferred salt of compounds of the present invention is the hydrochloride salt.
The pharmaceutically acceptable acid addition salts are 3o typically formed by reacting a compound of formula I with one equivalent (or slight excess) of acid. The reactants are generally combined in a mutual solvent such as diethyl ether, methanol, ethanol, or aqueous alcohol. The salt normally precipitates out of solution within about one hour to 10 days and can be isolated by filtration or the solvent can be stripped off by conventional means.
The pharmaceutically acceptable salts generally have enhanced solubility characteristics compared with the compound from which they are derived, and thus are often more amenable to formulation in solution or emulsion formulations.
For administration to a patient, the compounds of the present invention are formulated into a pharmaceutical formulation using standard practices well known in the formulation art. The present invention also provides pharmaceutical compositions which comprise compounds of the present invention formulated together with one or more non-toxic pharmaceutically acceptable carriers and/or excipients.
The formulations may be specially formulated for oral administration in solid or liquid form, for parenteral injection, or for rectal or vaginal administration by means of a suppository.
2o The pharmaceutical compositions of this invention can be administered to humans and other mammals orally, rectally, intravaginally, parenterally, topically (by means of powders, ointments, creams, or drops), bucally or sublingually, or as an oral or nasal spray. The term "parenteral administration" refers herein to modes of administration which include intravenous, intramuscular, intraperitoneal, instrasternal, subcutaneous, or intraarticular injection or infusion.
Pharmaceutical compositions of this invention for parenteral administration comprise sterile aqueous or non-aqueous solutions, dispersions, suspensions, or emulsions, as well as sterile powders which are reconstituted immediately prior to use into sterile solutions or suspensions. Examples of suitable sterile aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, physiological saline solution, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol), and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity is maintained, for example, by the use of coating materials such as lecithin, by the maintenance of proper particle size in the case of dispersions and suspensions, and by the use of surfactants.
1o Parenteral compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms is ensured by the inclusion of antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of injectable formulations may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and 2o gelatin.
In some cases, in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug following subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension or crystalline or amorphous material of low water solubility or by dissolving or suspending the drug in an oil vehicle. In the case of the subcutaneous or intramuscular injection of a suspension containing a form of the drug with low water solubility, the rate of absorption of the drug depends upon 3o its rate of dissolution.
Injectable "depot" formulations of the compounds of this invention are made by forming microencapsulated matrices of the drug in biodegradable polymers such as poly(lactic acid), poly(glycolic acid), copolymers of lactic and glycolic acid, poly (orthoesters), and poly (anhydrides) these materials which are described in the art.
Depending upon the ratio of drug to polymer and the characteristics of the particular polymer employed, the rate of drug release can be controlled.
Injectable formulations are sterilized, for example, by filtration through bacterial-retaining filters, or by presterilization of the components of the mixture prior to their admixture, either at the time of manufacture or just to prior to administration (as in the example of a dual chamber syringe package).
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active component is mixed with at t5 least one inert, pharmaceutically acceptable carrier such as sodium citrate, or dicalcium phosphate, and/or (a) fillers or extenders such as starches, lactose, glucose, mannitol, and silicic acid, (b) binding agents such as carboxymethylcellulose, alginates, gelatin, 2o poly(vinylpyrrolidine), sucrose and acacia, D humectants such as glycerol, (d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, silicates and sodium carbonate, (e) solution retarding agents such as paraffin, (f) absorption accelerating agents 25 such as quaternary ammonium compounds, (g) wetting agents such as cetyl alcohol and glycerin monostearate, (h) absorbents such as kaolin and bentonite clay, and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols), sodium lauryl 3o sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also contain buffering agents.
Solid compositions of a similar type may also comprise the fill in soft or hard gelatin capsules using excipients such as lactose as well as high molecular weight polyethylene glycols) and the like.
Solid dosage forms such as tablets, dragees, capsules, pills and granules can also be prepared with coatings or shells such as enteric coatings or other coatings well known in the pharmaceutical formulating art. The coatings may contain opacifying agents or agents which release the active ingredients) in a particular part of the digestive tract, as for example, acid soluble coatings for release of the 1o active ingredients) in the stomach, or base soluble coatings for release of the active ingredients) in the intestinal tract.
The active ingredients) may also be microencapsulated in a sustained-release coating, with the microcapsules being made part of a pill of capsule formulation.
Liquid dosage forms for oral administration of the compounds of this invention include solution, emulsions, suspensions, syrups and elixirs. In addition to the active components, liquid formulations may include inert diluents 2o commonly used in the art such as water or other pharmaceutically acceptable solvents, solubilizing agents and emulsifiers such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, ground nut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols), fatty acid esters of sorbitol, and mixtures thereof.
Besides inert diluents, the liquid oral formulations 3o may also include adjuvants such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.
Liquid suspension, in addition to the active ingredients) may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite clay, agar-agar, and tragacanth, and mixtures thereof.
Compositions for rectal or intravaginal administration are prepared by mixing one or more compounds of the present invention with suitable non-irritating excipients such as cocoa butter, polyethylene glycol or any suppository wax which is a solid at room temperature, but liquid at body io temperature and therefore melt in the rectum or vaginal cavity to release the active component(s). The compounds are dissolved in the melted wax, formed into the desired shape, and allowed to harden into the finished suppository formulation.
Compounds of the present invention may also be administered in the form of liposomes. As is know in the art, liposomes are generally derived from phospholipids or other lipid substances. Lipososome formulations are formed by mono- or multilamellar hydrated liquid crystals which are 2o dispersed in an aqueous medium. Any non-toxic, pharmaceutically acceptable, and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to one or more active compounds of the present invention, stabilizers, excipients, preservatives, and the like. The preferred lipids are phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic.
Methods for forming liposomes are know in the art as described, for example, in Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N. Y. (1976), p. 33 et seq.
Dosage forms for topical administration of the compounds of the present invention include powders, sprays, ointments, creams, and inhalants. The active ingredients) is mixed under sterile conditions with a suitable pharmaceutically acceptable carrier and preservatives, buffers, or propellants as needed. Opthalmic formulations, eye ointments, and solutions are also contemplated as falling within the scope of the present invention.
Actual dosage levels of compounds of the present invention are varied so as to administer an amount of the compound which is effective to bring about the desired therapeutic affect. The dose required for a given patient io will vary depending upon the severity of the condition being treated, the age, weight, and sex of the patient, as well as the state of health of the patient. However, it is within the skill of the art to "dose titrate" the patient; that is, to begin administering a dose known to be below the amount ~5 required to bring about the desired therapeutic effect and to gradually increase the dose until the desired effect is achieved.
Generally, for the treatment of estrogen-related disorders, compounds of the present invention are 2o administered at dosage levels between about 10 mg/kg of body weight and about 250 mg/kg of body weight per day. If desired, the daily dosage may be divided into multiple doses for purposes of administration, e.g. into two to four doses per day.
25 The following Examples are provided in order to enable one skilled in the art to practice the present invention.
However, the Examples are merely illustrative of the invention and are not to be read as limiting its scope which is defined by the appended claims.
Preparation 1 Preparation of acid chloride form of carboxypolystyrene resin To a suspension of carboxypolystyrene resin (20.0 g, Novabiochem, La Jolla, California, 92039) in benzene (200 mL) under nitrogen atmosphere was added dropwise and excess (20.0 mL) of oxalyl chloride. The resulting mixture was heated to 70°C for 20 hours, then cooled to ambient temperature. Additional benzene (100 mL) was added to the mixture which was stirred for 5 minutes, and the resulting resin allowed to settle. The supernate was removed via cannula. This procedure was repeated 5 times using 200 ml 1o benzene. After the final rinse, the resulting resin was dried under reduced pressure at 30°C until a constant mass (19.8 g) was obtained. Chlorine analysis showed the resin contained 8.09 C1 which corresponded to a new loading ratio of 2.29 mmol/g.
Preparatioa 2 Preparation of a Mixture of the Resin-Bound Phenolic Substrates HO HO
OMOM Resin O
and O
Resin O Ip MOMO
Zti!
Step 1 - Preparation of 6-methoxy-2-(4-methoxypheny_1)-1-(4-triisopropylsilyloxybenzoyl)-3,4-dihydro-naphthalene TI PSO
To a solution of 5.9 g (15.28 mmol) of 6-methoxy-2-(4-methoxyphenyl)-1-(4-hydroxybenzoyl)-3,4-dihydronaphthalene (prepared as described in Jones, et al., J. Med. Chem., 35:
*rB
931-938 (1992) in 200 mL of dichloromethane under a nitrogen atmosphere was added 1.87 g (15.28 mmol) of dimethylamino-pyridine and 4.1 mL (15.28 mmol) of triisopropyl trifluoromethane-sulfonate ("TIPS triflate," Aldrich Chemical Co., Milwaukee, WI). The resulting mixture was stirred at room temperature for 48 hours, after which time the reaction was quenched by addition of aqueous sodium bicarbonate solution. The resulting mixture was extracted twice with dichloromethane. The organic layers were combined, extracted with brine solution, dried over anhydrous sodium sulfate and concentrated under vacuum to yield 8.05 g (97~) of the title compound as a thick yellow oil.
1H NMR (300 MHz, CDC13). b Values: 1.06 (s, 9H), 1.19 (m, 1H), 2.79 2H), 3.01 (t, J 7.7, 7.8, 2H),3.69 (s, 3H), (m, =
3.79 (s, 3H),6.61-6.79 (m, 6H), 6.96 (d, J 8.49, 1H), =
7.17 (d, J 6.8, 2H), and 7.73 (d, = 7.13, 2H).
= J
Step 2 - Preparation of 6-hydroxy-2-(4-hydroxyphenyl)-1-(4-triisopropylsilyloxybenzyl)naphthalene TIPSO
OH
HO
To a solution of 8.05 g (14.85 mmol) of the product of step 1 in 200 mL of dichloromethane under a nitrogen atmosphere was added 5.8 mL (78.85 mmol) of ethanethiol followed by 8.41 g (63.08 mmol) of anhydrous aluminum chloride. The resulting mixture was stirred at room temperature for one hour and then cooled to 0°C. The cooled reaction mixture was quickly quenched by the addition of 3o saturated aqueous sodium bicarbonate. Water was added and the mixture was extracted three times with ethyl acetate.
The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, and concentrated under vacuum to yield 7.2 g of 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(triisopropylsilyloxy)benzoyl]naphthalene as a yellow solid.
This material was dissolved in 400 mL of tetrahydro-furan under a nitrogen atmosphere and the resulting mixture was cooled to 0°C. Lithium aluminum hydride (42 mL of a 1.0 M solution (42.0 mmol) was added dropwise to the cooled solution with vigorous stirring. This reaction mixture was stirred for 1.5 hours after which time the reaction was quenched by the addition of saturated aqueous sodium bicarbonate. The resulting mixture was extracted three time with ethyl acetate and the organic layers were combine, extracted with brine, dried over anhydrous sodium sulfate, t5 and conentrated under vacuum. The solid residue was taken up in 300 mL of ethyl acetate and a catalytic amount of gaseous hydrogen chloride was bubbled through the solution.
The solution was stirred at room temperature for 30 minutes and then quenched with saturated aqueous sodium bicarbonate solution.
This mixture was extracted three times with ethyl acetate, and the organic layers were combines, extrcated with brine, dried over sodium sulfate, and concentrated under vacuum to yield 2.8 g (5.61 mmol, 38~) of the title compound as a yellow foam.
1H NMR (300 MHz, CDC13). 8 Values: 1.06 (s, 9H), 1.19 (m, 1H), 4.31 (s, 2H), 4.71 (s, 1H), 4.99 (s, 1H), 6.72 - 6.85 (m, 6H), 7.02 (dd, J = 6.6, 2.5, 1H), 7.14 (d, J = 8.4, 2H), 7.19 (d, J = 2.5, 2H), 7.40 (d, J = 8.8, 1H), 7.65 (d, ?J =
8.5, 1H), and 7.83 (d, J = 9.1, 1H).
Step 3 - Preparation of mixture of 6-hydroxy-2-(4-metho methoxyphenyl)-1-(4-triisopropylsilyloxybenzoy_1_)-naphthalene and 6-methoxymethoxy-2-(4-hydroxy-phenyl)-1-(4-triisopropylsilyloxybenzoyl)-naphthalene TIPSO TIPSO
OMOM OH
HO~ MOMO
The product of step 2 (2.8 g, 5.61 mmol) was dissolved in 200 mL of acetonitrile under nitrogen at room 1o temperature. To this mixture were 0.78 g (5.61 mmol) of potassium carbonate and a catalytic amount (20 mg) of 1,4,7,10,13,16-hexaoxacyclooctadecane ("18-crown-6" ether, Aldrich Chemical Co., Milwaukee, WI, USA) and 0.43 mL (5.61 mmol) of methoxymethyl chloride (Aldrich Chemical Co., Milwaukee, WI, USA). This mixture was stirred at room temperature for 24 hours after which time the reaction was quenched by the addition of saturated sodium bicarbonate.
The reaction mixture was extracted three times with ethyl acetate and the organic layers combined and extracted 2o with brine solution. The organic solution was dried over anhydrous sodium sulfate and concentrated under vacuum.
Flash chromatograohy of the resulting oil on silica, eluting with dichloromethane yielded 1.37 g (45~) of a mixture of the two products as a yellow foam.
Step 4 - Preparation of mixture of resin-bound 6-hvdroxv-2 (4-methoxymethoxyphenyl)-1-(4-triisopropyl-silyloxybenzoyl)naphthalene and 6-methoxymethoxy-2-(4-hydroxyphenyl)-1-(4-triisopropylsilyloxy-benzoyl)naphthalene TIPSO TIPSO
Resin OMOM ' O
O O
O MOMO~
Resin To a solution in 25 mL of dichloromethane of 1.88 g (3.46 mmol) of the product mixture from step 3 were added, under nitrogen, 0.97 mL (6.92 mmol) of triethylamine and 1.51 g (3.46 mmol) of the resin in its acid chloride form (prepared as described in Preparation 1 above). The mixture was stirred gently at room temperature for 19 hours. After this time the reaction was quenched by the addition of 2 mL
of methanol and the resulting mixture was stirred at room temperature for an additional 5 minutes. The reaction mixture was filtered and the filter residue was washed successively with 150 mL portions of dichloromethane, methanol, and dichloromethane to yield 2.95 g of the loaded 2o resin with a loading ratio of 1.17 mmol/g.
Step 5 - Preparation of the mixture of resin-bound 6-hydroxy-2-(4-methoxymethoxyphenyl)-1-(4-hydroxybenzyl)naphthalene and 6-metho_x_y-methoxy-2-(4-hydroxyphenyl)-1-(4-hydroxybenzyl)-naphthalene HO HO
OMOM Resin O
O and O
Resin O ~ MOMO
Z~
preparation 3 Preparation of the Betaine Coupling Catalyst O;g~O PPh3 After the method of J. Castro, et al., J. Org. Chem., 59:2289-2291 (1994), to a stirred mixture of triphenyl-phosphine (8.73 g, 33.28 mmol) and 5.0 g (33.28 mmol) of 3,3-dimethyl-1,2,5-thiazolidine 1.1-dioxide in 100 mL of tetrahydrofuran under nitrogen were added, dropwise over a period of ten minutes, 5.25 mL (33.28 mmol) of diethylazo-dicarboxylate (DEAD). The resulting mixture was stirred at room temperature for 3 hours and the white solid precipitate which formed was collected by filtration and washed successively once with 20 mL of tetrahydrofuran and twice with 20 mL portions of diethyl ether. The material was dried under high vacuum over phosphorus pentoxide to yield 13.2 g (96~) of the title betaine, m.p. 169-172°C.
General Method for the Preparation of the Compounds of 8xamples 1-16 Z.Y,X.O Z.Y,X.O
OMOM Resin O
O aad O
Resin O ~ MOMO- v "
$2 Step 1 Coupling of the resin-bound and substrate alcohols Reactions were run in a 96-well plate which had been drilled and fitted with filter frits. A mixture of the substrate alcohol (0.4 mL of a 1 molar solution in toluene, 0.04 mmol), 30 mg of the loaded resin beads (0.04 mmol), and 0.4 mmol (0.4 mL of a 1 molar suspension in dichloromethane) were placed in each of well.
The plate was sealed and rotated for 168 hours at room temperature. At the end of this time, each well was filtered through its frit and the residue was washed successively with portions of tetrahydrofuran, dichloro-methane, dimethylformamide, methylene chloride, and tetrahydrofuran.
1o _Step 2 Cleavage of the derivatized, methoxymethyl-protected intermediates from the resin To each cell was added 0.8 mL of a 20~ solution of n-propylamine in tetrahydrofuran. The plated was sealed and vortexed for 24 hours. The contents of each cell were filtered into a normal 96-well plate, collecting each of the cleaved, methoxymethyl-protected intermediates in its own well on the new plate. Each transferred was followed by a rinse of the reaction cells with 15~ dichloromethane in methanol.
Step 3-- Removal of the methoxymethyl protecting grou To each cell of the new plate containing the cleaved intermediates described in step 2 was added 3.2 mmol of HC1 (4 molar in dioxane). The plate was sealed and vortexed overnight. At the end of this time, the solvent and excess HC1 were removed under vacuum to yield, in each well of the plate, the end-product of each Example below.
While standard methods of combinatorial chemistry were employed in preparing small amounts of each compound 3o exemplified below, it is within the skill of a practitioner of the organic chemical art to employ the reactions and reagents taught to prepare larger amounts of the compounds if needed.
WO 99/07377 PCT/iJS98/16065 Exaa~les 1-16 Each of the Examples below were prepared by the method detailed above. In each case, the molecular weight of the title compound was determined by the ion spray mass spectrometric method and the biological activity determined by the assay described below.
Example 1 OH
"., 6-Hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-methylpyrrolidin-2-yl)methoxy-benzyljnaphthalene hydrochloride C29H29N03~HCl Mass: (Calc.): 439 (-HC1) (Found): 440 Inhibition of MCF7 cell proliferation: ED50 = 0.5 nM
2o Exaa4ple a 6-Hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N,N-diethylamino) propoxy)benzyl]naphthalene hydrochloride C28H29N03~HC1 Mass: (Calc.): 455 (-HC1) (Found): 456 Inhibition of MCF7 cell proliferation: ED50 = 0.9 nM
Bxample 3 CH3 ~ HCI
H9C "N
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(N,N-diisopropyl-amino)ethoxy)benzyl]naphthalene hydrochloride C31H35N03~HC1 Mass: (Calc.): 469 (-HC1) (Found): 469 Inhibition of MCF7 cell proliferation: ED50 = 2 nM
8xample 4 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-methylpiperidin-2-yl) methoxybenzyl]naphthalene hydrochloride ..
N
i ~ HCI
C29H29N03~HCl Mass: (Calc.): 453 (-HC1) (Found): 454 Inhibition of MCF7 cell proliferation: ED50 = 2 nM
Example 5 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-methylpiperidin-3-yl) methoxybenzyl]naphthalene hydrochloride .N(~0 HCI OH
/~
HO ~
C30H31N03~HCl Mass: (Calc.): 453 (-HC1) (Found): 454 Inhibition of MCF7 cell proliferation: ED50 = 2 nM
~o 8xamyle 6 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(N,N-di-n-butylamino) ethoxy)benzyl]naphthalene hydrochloride H3C~N~0 /
~ J HCI ~ OH
H3C' v /
/
HO
C33H39N03~HC1 Mass: (Calc.): 497 (-HC1) (Found): 498 Inhibition of MCF7 cell proliferation: ED50 = 2 nM
$xampl~ 7 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N,N-di-n-butylamino) propoxy)benzyl]naphthalene hydrochloride C34H41N~3'HC1 Mass: (Calc.): 511 (-HC1) (Found): 512 Inhibition of MCF7 cell proliferation: EDS~ = 4 nM
io 8xam~le 8 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-(4-acetylphenyl)piperazin-1-yl)ethoxy)benzyl]-naphthalene dihydrochloride N~
OH
H3C ~ ~ 2 HCI
O
C37H36N2~4'2 HCl Mass: (Calc.): 572 (- 2 HC1) (Found): 573 2o Inhibition of MCF7 cell proliferation: EDS~ = 4 nM
Example 9 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(naphth-1-ylamino)propoxy)benzyl]naphthalene hydrochloride H
NCO
~ HCI E O
O
C36H31N03'HC1 Mass: (Calc.): 525 (-HC1) (Found): 526 Inhibition of MCF7 cell proliferation: ED50 - 9 nM
Exaa4ple 10 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N,N-di-n-butylamino) hexoxy)benzyl]naphthalene hydrochloride ~ HCI
C3~H4~N03~HC1 Mass: (Calc.): 525 (Found): 526 Inhibition of MCF7 cell proliferation: ED50 = 10 nM
Exan~yle 11 N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl methyl)phenoxy)ethyl]-N'-5-chloro-2 methylphenyl urea CI
N~N~/O /
H3 H ~CH ~ ~ / OH
/ /
HO
Mass: (Calc.): 580 (Found):
1o Inhibition of MCF7 cell proliferation: ED50 = 10 nM
Example 12 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(2,3,5,6 tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl)ethoxy)benzyl)naphthalene CH3 H ~ HCI
O~N N~ ~
H C~N T 'N
O
C32H30N4~5 Mass: (Calc.): 550 (Found): 548 Inhibition of MCF7 cell proliferation: ED50 = 20 nM
8xample 13 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(2,6 dimethylmorpholin-4-yl)ethoxy)benzyl]naphthalene hydrochloride HCI
H3C~N~0 O J ~ I / OH
HO
C31H33N~4'HC1 Mass: (Calc.): 483 (-HCl) (Found): 483 Inhibition of MCF7 cell proliferation: ED50 = 20 nM
8xaa~ple 14 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(azaspiro[5.5]undec-4 yl)propoxy)benzyl]naphthalene hydrochloride NCO
HCI ~ ( OH
HO
C36H41N~3'HC1 Mass: (Calc.): 535 (-HC1) (Found): 536 Inhibition of MCF7 cell proliferation: ED50 = 30 nM
8xam~le 15 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(pyrollidinon-1 yl)ethoxy)benzyl]naphthalene NCO
I ~ off I
Ho ~
C29H27N~4 Mass: (Calc.): 453 (Found): 454 Inhibition of MCF7 cell proliferation: ED50 = 40 nM
8xaa~ple 16 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(pyrollidinon-2 yl)propoxy)benzyl]naphthalene I
O OH
nv C30H29N~4 Mass: (Calc.): 467 (Found): 468 Inhibition of MCF7 cell proliferation: ED50 = 30 nM
Biological Activity of the Compounds of the Present Invention - MCF-7 Proliferation Assay The data reported in each of the Examples given above for inhibition of MCF-7 cell proliferation were obtained in an assay which determined each compound's ability to inhibit the proliferation of MCF-7 breast adenocarcinoma cells.
In the assay, these cells (ATCC HTB 22) are maintained in minimal essential medium, phenol red-free, (Sigma, St.
Louis, MO) supplemented with 10~ (V/V) fetal bovine serum (FBS), L-glutamine (2 mM), sodium pyruvate (1 mM), HEPES
~(N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid] 10 mM}, non-essential amino acids and bovine insulin (1 ug/mL) (maintenance medium). Ten days prior to assay, MCF-7 cells 1o are switched to maintenance medium supplemented with 10~
dextran coated charcoal stripped fetal bovine serum (DCC-FBS) assay medium) in place of 10~ FBS to deplete internal stores of steroids. MCF-7 cells are removed from maintenance flasks using cell dissociation medium (Ca++/Mg++
free HBSS (phenol red-free) supplemented with 10 mM HEPES
and 2 mM EDTA). Cells are washed twice with assay medium and adjusted to 80,000 cells/mL. Approximately 100 mL
(8,000 cells) are added to flat-bottom microculture wells (Costar 3596) and incubated at 37° C in a 5~ C02 humidified 2o incubator for 48 hours to allow for cell adherence and equilibration after transfer. Serial dilutions of drugs or DMSO as a diluent control are prepared in assay medium and 50 mL transferred to triplicate microcultures followed by 50 mL assay medium for a final volume of 200 mL. After an additional 48 hours at 37° C in a 5~ C02 humidified incubator, microcultures are pulsed with tritiated thymidine (1 uCi/well) for 4 hours. Cultures are terminated by freezing at -70° C for 24 hours followed by thawing and harvesting of microcultures using a Skatron Semiautomatic Cell Harvester. Samples are counted by liquid scintillation using a Wallac BetaPlace ~ counter. Activity of a compound of formula I in this present assay demonstrates that the compound is of potential value for treating hormonally-dependent cancer, particularly breast cancer.
Claims (17)
1, A compound of the structure:
or a pharmaceutically acceptable salt thereof wherein R1 and R2 are independently selected from the group consisting of hydrogen, alkyl of one to six carbon atoms, aryl of two to six carbon atoms, and phenacyl;
X is -(CH2)n where n is an integer of one to 6, inclusive;
Y is absent or is selected from the group consisting of 1,4-piperazinylene;
ureido;
N-(lower alkyl)ureido;
N'-(lower alkyl)ureido; and N,N'-(di-lower alkyl ureido;
Z is selected from the group consisting of 1-, 2- or 3-pyrrolidinyl;
1-, 2-, or 3-[1-(lower alkyl)pyrrolidinyl];
1- 2-,3- or 4-piperidinyl;
1-, 2-, 3- or 4-[1-lower alkyl)piperidinyl];
N,N-dialkyl in which the alkyl groups are independently from one to four carbon atoms;
1-azepinyl;
1- or 2-naphthylamino, 4-morpholinyl, dimethyl-4-morpholinyl, 3-azaspiro[5.5]undecan-3-yl;
pyrrolidinon-1-yl;
unsubstituted phenyl; and phenyl substituted with one or two groups independently selected from acyl of two to four carbon atoms, alkyl of one to four carbon atoms, halo, and alkoxy of one to four carbon atoms;
with the proviso that n is not 2 or 3 when Z is
1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, N,N-dimethylamino or N,N-diethyl-amino.
2. A compound as defined by Claim 1 or a pharmaceutically acceptable salt thereof wherein Y is absent.
3. A compound as defined by Claim 2 having the structure or a pharmaceutically acceptable salt thereof wherein n is one or an integer of from four to six and Z
is selected from the group consisting of 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, dimethyl-4-morpholinyl, and N,N-dialkyl in which the alkyl groups are independently of one to four carbon atoms.
is selected from the group consisting of 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, dimethyl-4-morpholinyl, and N,N-dialkyl in which the alkyl groups are independently of one to four carbon atoms.
4. A compound as defined by Claim 3, or a pharmaceutically acceptable salt thereof, having the name 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-methylamino)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N,N-dimethylamino)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-isopropylamino)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N,N-diisopropyl-amino)methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(N-isopropyl-amino)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N-isopropyl-amino)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N,N-diisopropyl-amino)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N-butylamino)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N,N-dibutyl-amino)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N-methylamino)-hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N,N-dimethyl-amino)hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N-ethylamino)-hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N,N-diethylamino)hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N-isopropyl-amino)hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N,N-diisopropyl-amino)hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N-butylylamino)-hexoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N,N-dibutyl-amino)hexoxy)benzyl]naphthalene.
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N,N-dimethylamino)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-isopropylamino)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N,N-diisopropyl-amino)methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(N-isopropyl-amino)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N-isopropyl-amino)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N,N-diisopropyl-amino)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N-butylamino)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(N,N-dibutyl-amino)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N-methylamino)-hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N,N-dimethyl-amino)hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N-ethylamino)-hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N,N-diethylamino)hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N-isopropyl-amino)hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N,N-diisopropyl-amino)hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N-butylylamino)-hexoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(N,N-dibutyl-amino)hexoxy)benzyl]naphthalene.
5. A compound as defined by Claim 3, or a pharmaceutically acceptable salt thereof, having the name 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(pyrrolidin-1-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(pyrrolidin-2-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(pyrrolidin-3-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(pyrrolidin-2-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(pyrrolidin-3-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(pyrrolidin-2-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(pyrrolidin-3-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(pyrrolidin-1-yl)butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(pyrrolidin-2-yl)butoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(pyrrolidin-3-yl)butoxy)benzyl]naphthalene.
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(pyrrolidin-2-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(pyrrolidin-3-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(pyrrolidin-2-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(pyrrolidin-3-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(pyrrolidin-2-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(pyrrolidin-3-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(pyrrolidin-1-yl)butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(pyrrolidin-2-yl)butoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(pyrrolidin-3-yl)butoxy)benzyl]naphthalene.
6. A compound as defined by Claim 3, or a pharmaceutically acceptable salt thereof, having the name 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(piperidin-1-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(piperidin-2-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-methylpiperidin-2-yl)methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(piperidin-3-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-methylpiperidin-3-yl)methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(piperidin-4-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(piperidin-2-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(piperidin-3-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(piperidin-4-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(piperidin-2-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(piperidin-3-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(piperidin-4-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(piperidin-1-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(piperidin-2-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(piperidin-3-yl)-butoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(piperidin-4-yl)-butoxy)benzyl]naphthalene.
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(piperidin-2-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-methylpiperidin-2-yl)methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(piperidin-3-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(N-methylpiperidin-3-yl)methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(piperidin-4-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(piperidin-2-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(piperidin-3-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(piperidin-4-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(piperidin-2-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(piperidin-3-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(piperidin-4-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(piperidin-1-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(piperidin-2-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(piperidin-3-yl)-butoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(piperidin-4-yl)-butoxy)benzyl]naphthalene.
7. A compound as defined by Claim 3, or a pharmaceutically acceptable salt thereof, having the name 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(azepin-1-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(azepin-2-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(azepin-3-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(azepin-4-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(azepin-2-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(azepin-3-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(azepin-2-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(azepin-3-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(4-(azepin-1-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(azepin-2-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(azepin-3-yl)-butoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(azepin-4-yl)-butoxy)benzyl]naphthalene.
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(azepin-2-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(azepin-3-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(azepin-4-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(azepin-2-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(azepin-3-yl)-ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(azepin-2-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(azepin-3-yl)-propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(4-(azepin-1-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(azepin-2-yl)-butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(azepin-3-yl)-butoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(azepin-4-yl)-butoxy)benzyl]naphthalene.
8. A compound as defined by Claim 3, or a pharmaceutically acceptable salt thereof, having the name 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(morpholin-4-yl-methoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[(4-(4-(morpholin-4-yl)butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(5-(morpholin-4-yl)-pentoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(morpholin-4-yl) hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2,6-dimethyl-morpholin-4-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(2,6-dimethyl-morpholin-4-yl)ethoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(2,6-dimethyl-morpholin-4-yl)propoxy)benzyl]naphthalene.
6-hydroxy-2-(4-hydroxyphenyl)-1-[(4-(4-(morpholin-4-yl)butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(5-(morpholin-4-yl)-pentoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(6-(morpholin-4-yl) hexoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2,6-dimethyl-morpholin-4-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(2,6-dimethyl-morpholin-4-yl)ethoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(2,6-dimethyl-morpholin-4-yl)propoxy)benzyl]naphthalene.
9. A compound as defined by Claim 2, or a pharmaceutically acceptable salt thereof, selected from the group consisting of 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-azaspiro-[5.5]under-3-yl)methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(3-azaspiro-[5.5]under-3-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(3-azaspiro-[5.5]under-3-yl)propoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(3-azaspiro-[5.5]undec-3-yl)butoxy)benzyl]naphthalene.
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(3-azaspiro-[5.5]under-3-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(3-azaspiro-[5.5]under-3-yl)propoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(3-azaspiro-[5.5]undec-3-yl)butoxy)benzyl]naphthalene.
10. A compound as defined by Claim 2, or a pharmaceutically acceptable salt thereof, having the name 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(naphth-1-ylamino)-methoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(naphth-1-yl-amino)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(naphth-1-yl-amino)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(naphth-1-yl-amino)butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(naphth-2-ylamino)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(naphth-2-yl-amino)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(naphth-2-yl-amino)propoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(naphth-2-yl-amino)butoxy)benzyl]naphthalene.
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(naphth-1-yl-amino)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(naphth-1-yl-amino)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(naphth-1-yl-amino)butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(naphth-2-ylamino)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(naphth-2-yl-amino)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(naphth-2-yl-amino)propoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(naphth-2-yl-amino)butoxy)benzyl]naphthalene.
11. A compound as defined by Claim 2, or a pharmaceutically acceptable salt thereof, having the name 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(pyrrolidinon-1-yl)-methoxybenzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(pyrrolidinon-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(pyrrolidinon-1-yl)propoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(pyrrolidinon-1-yl)butoxy)benzyl]naphthalene.
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(pyrrolidinon-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(pyrrolidinon-1-yl)propoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(pyrrolidinon-1-yl)butoxy)benzyl]naphthalene.
12. A compound as defined by Claim 2, or a pharmaceutically acceptable salt thereof, having the name 6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(2,3,5,6-tetrahydro 2,6-dioxo-1,3-dimethyl-1H-purin-8-yl)methoxy benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(2,3,5,6-tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(2,3,5,6-tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl)propoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(4-(2,3,5,6-tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl)butoxy)benzyl]naphthalene.
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(2,3,5,6-tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(2,3,5,6-tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl)propoxy)benzyl]naphthalene; or 6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(4-(2,3,5,6-tetrahydro-2,6-dioxo-1,3-dimethyl-1H-purin-8-yl)butoxy)benzyl]naphthalene.
13. A compound as defined by Claim 1 or a pharmaceutically acceptable salt thereof wherein Z is 1,4-piperazinylene.
14. A compound as defined by Claim 14, or a pharmaceutically acceptable salt thereof, having the name 6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(4-phenylpiperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-phenyl-piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-phenyl-piperazin-1-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-phenyl-piperazin-1-yl)butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-methyl-phenyl)piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(4-(4-chloro-phenyl)piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-hydroxy-phenyl)piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-methoxy-phenyl)piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-acetyl-phenyl)piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-(4-methyl-phenyl)piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(2-(4-(4-chloro-phenyl)piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-(4-hydroxy-phenyl)piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-(4-methoxy-phenyl)piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-(4-acetyl-phenyl)piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-methyl-phenyl)piperazin-1-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-chloro-phenyl)piperazin-1-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-hydroxy-phenyl)piperazin-1-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-methoxy-phenyl)piperazin-1-yl)propoxy)benzyl]naphthalene;
or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-acetyl-phenyl)piperazin-1-yl)propoxy)benzyl]naphthalene.
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-phenyl-piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-phenyl-piperazin-1-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-phenyl-piperazin-1-yl)butoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-methyl-phenyl)piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(4-(4-chloro-phenyl)piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-hydroxy-phenyl)piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-methoxy-phenyl)piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(4-(4-acetyl-phenyl)piperazin-1-ylmethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-(4-methyl-phenyl)piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-(4-(2-(4-(4-chloro-phenyl)piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-(4-hydroxy-phenyl)piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-(4-methoxy-phenyl)piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(2-(4-(4-acetyl-phenyl)piperazin-1-yl)ethoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-methyl-phenyl)piperazin-1-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-chloro-phenyl)piperazin-1-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-hydroxy-phenyl)piperazin-1-yl)propoxy)benzyl]naphthalene;
6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-methoxy-phenyl)piperazin-1-yl)propoxy)benzyl]naphthalene;
or 6-hydroxy-2-(4-hydroxyphenyl)-1-[4-(3-(4-(4-acetyl-phenyl)piperazin-1-yl)propoxy)benzyl]naphthalene.
15. A compound as defined by Claim 1 or a pharmaceutically acceptable salt thereof wherein Y is selected from ureido, N-(lower alkyl)ureido, N'-(lower alkyl)ureido, and N,N'-di(lower alkyl)ureido having the name N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-phenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-phenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-phenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-4-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-4-chlorophenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-4-hydroxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-4-methoxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-3-chloro-2-methylphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-4-methylphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-4-chlorophenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-4-hydroxyphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-4-methoxyphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-3-chloro-2-methylphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-4-methylphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-phenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-4-chlorophenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-4-hydroxyphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-4-methoxyphenyl urea; and N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-3-chloro-2-methylphenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-phenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-phenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-phenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-methylphenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-chlorophenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-hydroxyphenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-methoxyphenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-3-chloro-2-methylphenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-methylphenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-chlorophenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-hydroxyphenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-methoxyphenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-3-chloro-2-methyl-phenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-methylphenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-phenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-chlorophenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-hydroxyphenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-methoxyphenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-3-chloro-2-methyl-phenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-methylphenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-2-ylmethyl)phenylmethyl]-N'-4-chlorophenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-hydroxyphenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-methoxyphenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-3-chloro-2-methylphenyl urea;
N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-methylphenyl urea;
N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-chlorophenyl urea;
N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-hydroxyphenyl urea;
N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-methoxyphenyl urea;
N-ethyl-N-(4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-3-chloro-2-methylphenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1 ylmethyl)phenylpropyl]-N'-4-methylphenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-phenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1 ylmethyl)phenylpropyl]-N'-4-chlorophenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-hydroxyphenyl urea;
N-ethyl-N-(4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-methoxyphenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-3-chloro-2-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-phenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl methyl)phenyl)ethyl]-N'-methyl-N'-phenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-ethyl-N'-phenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-4-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-4-chlorophenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-4-hydroxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-4-methoxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-3-chloro-2-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-ethyl-N'-4-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-ethyl-N'-4-chlorophenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-ethyl-N'-4-hydroxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl-N'-ethyl-N'-4-methoxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-ethyl-N'-3-chloro-2-methylphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-methyl-N'-4-methylphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-methyl-N'-4-chlorophenyl urea;
N-[4-(2-(6-hydro~y-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-methyl-N'-4-hydroxyphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-methyl-N'-4-methoxyphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-methyl-N'-3-chloro-2-methylphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-ethyl-N'-4-methylphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-ethyl-N'-phenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-ethyl-N'-4-chlorophenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'ethyl-N'-4-hydroxyphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-ethyl-N-4-methoxyphenyl urea; or N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1 yl-methyl)phenoxy)ethyl]-N'-5-chloro-2-methyl phenyl urea.
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-phenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-phenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-4-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-4-chlorophenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-4-hydroxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-4-methoxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-3-chloro-2-methylphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-4-methylphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-4-chlorophenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-4-hydroxyphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-4-methoxyphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-3-chloro-2-methylphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-4-methylphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-phenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-4-chlorophenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-4-hydroxyphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-4-methoxyphenyl urea; and N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-3-chloro-2-methylphenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-phenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-phenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-phenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-methylphenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-chlorophenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-hydroxyphenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-methoxyphenyl urea;
N-methyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-3-chloro-2-methylphenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-methylphenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-chlorophenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-hydroxyphenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-methoxyphenyl urea;
N-methyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-3-chloro-2-methyl-phenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-methylphenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-phenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-chlorophenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-hydroxyphenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-methoxyphenyl urea;
N-methyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-3-chloro-2-methyl-phenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-methylphenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-2-ylmethyl)phenylmethyl]-N'-4-chlorophenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-hydroxyphenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-4-methoxyphenyl urea;
N-ethyl-N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylmethyl]-N'-3-chloro-2-methylphenyl urea;
N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-methylphenyl urea;
N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-chlorophenyl urea;
N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-hydroxyphenyl urea;
N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-4-methoxyphenyl urea;
N-ethyl-N-(4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenyl)ethyl]-N'-3-chloro-2-methylphenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1 ylmethyl)phenylpropyl]-N'-4-methylphenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-phenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1 ylmethyl)phenylpropyl]-N'-4-chlorophenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-hydroxyphenyl urea;
N-ethyl-N-(4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-4-methoxyphenyl urea;
N-ethyl-N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)phenylpropyl]-N'-3-chloro-2-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-phenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl methyl)phenyl)ethyl]-N'-methyl-N'-phenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-ethyl-N'-phenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-4-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-4-chlorophenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-4-hydroxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-4-methoxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-methyl-N'-3-chloro-2-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-ethyl-N'-4-methylphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-ethyl-N'-4-chlorophenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-ethyl-N'-4-hydroxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl-N'-ethyl-N'-4-methoxyphenyl urea;
N-[4-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-ylmethyl)-phenylmethyl]-N'-ethyl-N'-3-chloro-2-methylphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-methyl-N'-4-methylphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-methyl-N'-4-chlorophenyl urea;
N-[4-(2-(6-hydro~y-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-methyl-N'-4-hydroxyphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-methyl-N'-4-methoxyphenyl urea;
N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenyl)ethyl]-N'-methyl-N'-3-chloro-2-methylphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-ethyl-N'-4-methylphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-ethyl-N'-phenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-ethyl-N'-4-chlorophenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'ethyl-N'-4-hydroxyphenyl urea;
N-[4-(3-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1-yl-methyl)phenylpropyl]-N'-ethyl-N-4-methoxyphenyl urea; or N-ethyl-N-[4-(2-(6-hydroxy-2-(4-hydroxyphenyl)naphth-1 yl-methyl)phenoxy)ethyl]-N'-5-chloro-2-methyl phenyl urea.
16. A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined by Claim 1 in combination with a pharmaceutically acceptable carrier.
17. A method for the prophylaxis or treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound as defined by Claim 1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5495297P | 1997-08-07 | 1997-08-07 | |
US60/054,952 | 1997-08-07 | ||
PCT/US1998/016065 WO1999007377A1 (en) | 1997-08-07 | 1998-08-04 | 1-[4-(substituted alkoxy)benzyl]naphthalene compounds having estrogen inhibitory activity |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2298651A1 true CA2298651A1 (en) | 1999-02-18 |
Family
ID=21994585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002298651A Abandoned CA2298651A1 (en) | 1997-08-07 | 1998-08-04 | 1-¬4-(substituted alkoxy)benzyl|naphthalene compounds having estrogen inhibitory activity |
Country Status (9)
Country | Link |
---|---|
US (1) | US6509356B1 (en) |
EP (1) | EP0895989B1 (en) |
JP (1) | JP2001513501A (en) |
AT (1) | ATE295834T1 (en) |
AU (1) | AU8683398A (en) |
CA (1) | CA2298651A1 (en) |
DE (1) | DE69830218T2 (en) |
ES (1) | ES2239793T3 (en) |
WO (1) | WO1999007377A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID19392A (en) | 1996-08-29 | 1998-07-09 | Lilly Co Eli | NAFTIL COMPOUNDS AND MIDDLE MATERIALS AND COMPOSITION AND USE METHODS |
WO2002094268A1 (en) * | 2001-05-22 | 2002-11-28 | Eli Lilly And Company | Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen |
WO2002094788A1 (en) | 2001-05-22 | 2002-11-28 | Eli Lilly And Company | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods |
US20050004164A1 (en) * | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
CN1910167B (en) * | 2004-01-22 | 2011-08-10 | 伊莱利利公司 | Selective estrogen receptor modulators for the treatment of vasomotor symptoms |
ATE476428T1 (en) | 2004-01-22 | 2010-08-15 | Lilly Co Eli | SELECTIVE MODULATORS OF THE ESTROGEN RECEPTOR FOR THE TREATMENT OF VASOMOTOR SYMPTOMS |
US20070111988A1 (en) * | 2004-01-22 | 2007-05-17 | Eli Lilly And Company | Selective estrogen receptor modulators |
WO2007040682A1 (en) | 2005-09-21 | 2007-04-12 | Decode Genetics Ehf. | Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation |
US7977346B2 (en) * | 2006-01-17 | 2011-07-12 | Guoqing Paul Chen | Spiro compounds and methods of use |
FR2913017A1 (en) * | 2007-02-23 | 2008-08-29 | Cerep Sa | New N-(substituted alkyl)-piperidine or piperazine derivatives, are cellular proliferation inhibitors useful e.g. for treating cancer or inflammatory or autoimmune diseases |
NZ591955A (en) | 2007-10-16 | 2011-10-28 | Repros Therapeutics Inc | Trans-clomiphene for diabetes mellitus type 2 |
EP2624697B1 (en) | 2010-10-04 | 2015-11-25 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators |
ES2681023T3 (en) | 2012-02-29 | 2018-09-11 | Repros Therapeutics Inc. | Combination therapy to treat androgen deficit |
EP3373967B9 (en) | 2015-11-10 | 2023-10-04 | Paracrine Therapeutics AB | Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen |
CN112105607B (en) * | 2018-01-22 | 2024-08-27 | 雷迪厄斯制药公司 | Estrogen receptor modulating compounds |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2703324A (en) * | 1950-08-30 | 1955-03-01 | Bristol Lab Inc | Basic ethers of aralkyl phenols and salts thereof |
US3274213A (en) | 1961-09-05 | 1966-09-20 | Upjohn Co | Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes |
US3396169A (en) | 1966-10-26 | 1968-08-06 | Upjohn Co | Substituted 2-phenyl-1-(tertiary-aminoalkoxy) phenyl-3, 4-dihydronaphthalenes |
US3396196A (en) * | 1963-12-19 | 1968-08-06 | Allied Chem | Process for preserving aqueous formaldehyde solutions |
GB1138163A (en) | 1965-05-21 | 1968-12-27 | Bristol Myers Co | Benzothiophene derivatives having anti-fertility properties |
US3394125A (en) | 1965-10-23 | 1968-07-23 | Bristol Myers Co | 2-phenyl-3-tertiary-aminoalkoxy phenyl-and corresponding tertiaryaminoalkyl thio benzfurans substituted in the benzo nucleus with an alkoxy or tertiaryamino alkoxy or alkylthio group |
US4230862A (en) | 1975-10-28 | 1980-10-28 | Eli Lilly And Company | Antifertility compounds |
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4358593A (en) | 1981-04-03 | 1982-11-09 | Eli Lilly And Company | Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes |
US4380635A (en) | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
PH18628A (en) | 1981-04-03 | 1985-08-23 | Lilly Co Eli | "6-hydroxy-2-(4-hydroxyphenyl)-3 4-(2- piperidine or 3-methylpyrollidine -benzo b thiophene compounds |
GR78370B (en) * | 1981-12-24 | 1984-09-26 | Delalande Sa | |
GB8311678D0 (en) | 1983-04-28 | 1983-06-02 | Ici Plc | Phenol derivatives |
WO1989002893A1 (en) | 1987-09-30 | 1989-04-06 | The University Of Tennessee Research Corporation | Certain 3-substituted 2-alkyl benzothiophene derivatives |
US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
DE4117512A1 (en) | 1991-05-25 | 1992-11-26 | Schering Ag | 2-PHENYLBENZO (B) FURANES AND THIOPHENES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
JP3157882B2 (en) | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | New benzothiophene derivatives |
US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
US5554628A (en) * | 1994-09-20 | 1996-09-10 | Eli Lilly And Company | Method for minimizing the uterothrophic effect of tamoxifen and tamoxifen analogs |
US7501441B1 (en) | 1994-09-20 | 2009-03-10 | Eli Lilly And Company | Naphthyl compounds, intermediates, processes, compositions, and methods |
US5658931A (en) * | 1994-09-20 | 1997-08-19 | Eli Lilly And Company | Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds |
US5541228A (en) * | 1994-10-14 | 1996-07-30 | Bristol-Myers Squibb Co. | Melatonergic agents |
US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
US5510357A (en) | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
US5998401A (en) | 1995-02-28 | 1999-12-07 | Eli Lilly And Company | Naphthyl compounds, intermediates, compositions, and methods |
US5811421A (en) * | 1995-07-31 | 1998-09-22 | Eli Lilly And Company | Naphthyl and dihydronaphthyl intermediates, compounds, compositions, and methods |
GB2312844A (en) * | 1996-05-07 | 1997-11-12 | Lilly Co Eli | A naphthyl compound for the treatment of immune-complex diseases |
-
1998
- 1998-08-04 AU AU86833/98A patent/AU8683398A/en not_active Abandoned
- 1998-08-04 WO PCT/US1998/016065 patent/WO1999007377A1/en active Search and Examination
- 1998-08-04 EP EP98306198A patent/EP0895989B1/en not_active Expired - Lifetime
- 1998-08-04 CA CA002298651A patent/CA2298651A1/en not_active Abandoned
- 1998-08-04 US US09/129,119 patent/US6509356B1/en not_active Expired - Fee Related
- 1998-08-04 ES ES98306198T patent/ES2239793T3/en not_active Expired - Lifetime
- 1998-08-04 AT AT98306198T patent/ATE295834T1/en not_active IP Right Cessation
- 1998-08-04 JP JP2000506967A patent/JP2001513501A/en not_active Withdrawn
- 1998-08-04 DE DE69830218T patent/DE69830218T2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69830218T2 (en) | 2006-02-02 |
EP0895989B1 (en) | 2005-05-18 |
ATE295834T1 (en) | 2005-06-15 |
EP0895989A1 (en) | 1999-02-10 |
ES2239793T3 (en) | 2005-10-01 |
DE69830218D1 (en) | 2005-06-23 |
AU8683398A (en) | 1999-03-01 |
US6509356B1 (en) | 2003-01-21 |
WO1999007377A1 (en) | 1999-02-18 |
JP2001513501A (en) | 2001-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0895989B1 (en) | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | |
US5723474A (en) | Benzothiophene compounds, intermediates, compositions, and methods | |
EA002360B1 (en) | Treatment of central nervous system disorders with selective estrogen receptor modulators | |
EP0835868B1 (en) | 2-Aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods | |
US5658931A (en) | Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds | |
US5554628A (en) | Method for minimizing the uterothrophic effect of tamoxifen and tamoxifen analogs | |
US5929090A (en) | 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods | |
US5856340A (en) | Method of treating estrogen dependent cancers | |
EP0873992B1 (en) | Indene compounds having activity as SERMs | |
CA2304138A1 (en) | Benzothiophenes | |
EP0832881B1 (en) | Benzofluorene compounds, intermediates, compositions, and methods | |
EP0835871B1 (en) | Benzo [b] thiophene compounds, intermediates, formulations, and methods | |
US5889000A (en) | Naphthofluorene compounds, intermediates, compositions and methods | |
KR20030076588A (en) | Novel Estrogen Receptor Ligands And MethodsⅢ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |